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Abstract III 
 
Abstract 
Several studies suggest that sodium is not only linked to extracellular fluids, but is also found in 
considerable amounts in other sites of the body including skin, muscle and arteries, where it is 
stored osmotically inactive, presumably bound to glycosaminoglycans. In a recent study, a corre-
lation between tissue sodium concentrations, glycosaminoglycan content and the expression of 
XYLT1, the enzyme initiating glycosaminoglycan synthesis, was found. Thus, the aim of the 
present in vitro study was to investigate the potential regulation of XYLT1 expression in human 
fibroblast cells, in order to gain further insight into potential regulatory mechanisms of tissue 
sodium storage. We hypothesized that XYLT1 expression can be actively induced by external 
stimuli. 
As a tool for internal control of successful stimulation, human immortalized dermal fibroblasts 
were stably transfected with pathway specific reporter plasmids (TGF-b/SMAD and NFAT5, re-
spectively), with a fluorescent protein read-out (Gaussia Luciferase), allowing the monitoring of 
pathway activation status in response to different experimental conditions. XYLT1 expression 
was quantified by real-time PCR.   
We observed significant induction of XYLT1 expression by treatment with TGF-b1 and TGF-b3. 
Media with hypertonic sodium, elevated Vasopressin, Endothelin-1 and FGF23 concentrations, 
respectively, did not have significant effects on XYLT1 expression.  
In conclusion, we established functioning systems to monitor pathway activation status as internal 
control of treatment with TGF-b and hypertonic sodium. Our data support the hypothesis that 
XYLT1 is actively regulated by TGF-b, which strengthens the theory that there is active regula-
tion of water-free sodium storage. To investigate this theory further, we suggest in vitro quantifi-
cation of sodium concentration and glycosaminoglycan content relative to XYLT1 expression as 
a next step. 
 
Kurzfassung IV 
 
Kurzfassung 
Etliche Studien weisen darauf hin, dass Natrium im Körper nicht nur an extrazelluläre Flüssigkeit 
gebunden ist, sondern auch in bedeutenden Mengen in anderen Bereichen des Körpers, wie Haut, 
Muskeln und Arterien, existiert, wo es - vermutlich an Glykosaminoglykane gebunden - osmo-
tisch inaktiv gespeichert wird. In einer kürzlich durchgeführten Studie wurde eine positive Kor-
relation zwischen Natriumkonzentrationen in Gewebe, Glykosaminoglykan-Gehalt und der Ex-
pression von XYLT1, dem Schlüsselenzym der Glykosaminoglykan-Synthese, gefunden. Das 
Ziel dieser Arbeit war deshalb, die Regulation von XYLT1 näher zu untersuchen, um bessere 
Einsicht in die regulatorischen Mechanismen von Gewebe-Natriumspeichern zu erlangen. Unsere 
Hypothese war, dass XYLT1-Expression durch externe Stimuli wie TGF-b aktiv induziert werden 
kann.  
Für die Stimulationsexperimente wurde folgendes in vitro Zellkulturmodel etabliert: Humane der-
male Fibroblasten wurden stabil mit TGF-b/SMAD oder NFAT5 Reportertransgenen transfiziert, 
um mittels eines fluoreszenten Reporterproteins den Aktivitätsstatus des jeweiligen Signalwegs 
unter verschiedenen experimentellen Bedingungen verfolgen zu können. Dies ermöglichte eine 
interne Kontrolle für erfolgreiche Stimulation. Nach Inkubation mit unterschiedlichen Stimuli 
wurde XYLT1 Expression mittels quantitativer Echtzeit-PCR bestimmt.  
Als Ergebnis zeigte sich eine starke Induktion der XYLT1 Expression nach Stimulation mit TGF-
b1 und TGF-b3. Inkubation mit erhöhten Konzentrationen von Natrium, Vasopressin, Endothe-
lin-1 oder FGF23 hatte dagegen keinen Effekt auf XYLT1 Expression, im Vergleich zur Kon-
trolle. 
Zusammenfassend wurde in dieser Arbeit ein funktionierendes System zur Überwachung des Ak-
tivitätsstatus von Signalwegen etabliert, das hier als Kontrolle für Stimulation mit TGF-b und 
hypertonem Natrium diente. Die Ergebnisse der Stimulationsexperimente unterstützen die Hypo-
these, dass XYLT1 aktiv durch TGF-b reguliert wird. Dies stärkt die Theorie, dass eine aktive 
Regulation der osmotisch inaktiven Gewebe-Natriumspeicher existiert. Um diese Theorie zu be-
legen, erscheint die Quantifizierung von Gewebe-Natriumkonzentration und Glykosaminogly-
kan-Gehalt in vitro relativ zu XYLT1 Expression ein wichtiger nächster Schritt.  
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1 Introduction 
1.1 Biological role of sodium            
Sodium is an essential electrolyte in humans and animals. As the major cation in extracellular 
fluids, it plays an important role in the regulation of blood pressure and acid-base balance and in 
maintenance of fluid balance with its ability to attract and hold water. Moreover, it is a central 
substance for building up membrane potential through the Na+/K+ ATPase, allowing muscles and 
nerves to carry electrical impulses. The concentrations of sodium in the extracellular fluid are 
normally maintained within a narrow range around 135-145 mmol/L, by the hypothalamic-renal 
feedback systems. However, serum sodium disturbances can develop by imbalanced elimination 
or ingestion of sodium. The resulting hyponatremia or hypernatremia can cause variable symp-
toms and can, in the worst case, be lethal, therefore they often require medical attention.  
1.2 Current paradigm regarding sodium handling in humans  
The common understanding of sodium handling is, as described in most textbooks, that sodium 
to a large extent, is linked to extracellular body fluids, perhaps with a minor component stored in 
bone tissue. It is generally assumed that serum sodium regulation functions as follows: Increase 
of dietary sodium intake leads to elevation of plasma osmolality, triggering thirst and the secretion 
of antidiuretic hormone while reducing aldosterone levels. Greater water intake combined with 
increased water retention lead to augmentation of circulating fluid volume and weight. Approxi-
mate 2-4 days are required to establish a new steady-state, in which urinary sodium excretion and 
sodium intake match (Walser, 1985). When dietary sodium intake is reduced, the mechanisms are 
reversed. Without doubt, this model is applicable in most clinical cases. However, there are ex-
tremes in the clinical spectrum that cannot be fully explained by the common understanding of 
sodium homeostasis. For example, there are observations of patients with severe kidney failure 
with increasing serum sodium levels, despite dialysis, and low sodium input. In the opposite ex-
treme, some anuric patients are to a certain extent, able to compensate for sodium loading. These 
observations suggest that sodium can be stored elsewhere in the body otherthan in extracellular 
fluids, and that sodium balance is a more complex biological process than previously assumed.   
1.3 Paradigm shift? - Water-free storage of sodium  
The presence of a slow exchangeable pool of body sodium was already hypothesized 60 years 
ago (Farber, 1960), (Streeten, Rapoport, & Conn, 1963), but eventually lost favor and was not 
actively pursued. However, in the last 20 years, the interest in sodium storage has been renewed. 
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A detailed balance study in 2000, in which healthy men were given high sodium intakes, contra-
dicted the equilibrium theory of sodium balance by showing no increase of total body water and 
no change in body weight despite increased total body Na+ (Heer, Baisch, Kropp, Gerzer, & 
Drummer, 2000). In another balance study in a long-term space flight simulation, sodium gain 
exceeded weight gain towards the end of isolation, suggesting sodium accumulation in an osmot-
ically inactive form. As a potential reservoir, bone, dense connective tissue or cartilage was pro-
posed (Titze, Maillet, et al., 2002). Recent studies with non-invasive 23Na-MRI measurements of 
Na+ content in tissue support this observation by demonstrating increased tissue sodium concen-
trations in skin and muscle in patients with primary hyperaldosteronism without apparent fluid 
retention or significant changes in Na+ concentration in serum (C. Kopp et al., 2012). The phe-
nomenon of osmotically inactive Na+ storage has also been confirmed experimentally in animals: 
A study in Sprague-Dawley rats showed that Na+ accumulated in skin after high NaCl diet, con-
cluding that osmotically inactive Na+ storage takes place largely in the skin (Titze et al., 2003).  
However, the mechanisms responsible for tissue Na+ storage are not fully understood. Various 
studies suggest incorporation into glycosaminoglycans (GAGs) as a potential site of sodium stor-
age. In rats exposed to sodium loading, increasing skin Na+ coincided with significant increases 
in glycosaminoglycan expression on Western blot of the skin (Titze et al., 2004). Long-term salt 
deprivation, conversely, resulted in reduced negatively charged skin glycosaminoglycan content 
and release of Na+ from the skin reservoir (Schafflhuber et al., 2007). The idea of sodium-prote-
oglycan binding was in fact found already four decades ago, based on GAG measurements in the 
skin of Wistar rats with different salt loads (Ivanova, Archibasova, & Shterental, 1978) and was 
also described in binding studies in glycosaminoglycan rich tissues (Mobasheri, 1998).  
 
 
 
 
 
 
 
 
Figure 1: Sodium balance 
Internal balance through exchange between sodium linked to body water and sodium that is bound to pro-
teoglycans in bone, cartilage and skin. Image adapted from Sterns (2015, p. 2). 
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Taken together, sodium is most likely stored water free in tissue and potentially bound to gly-
cosaminoglycans. However, the regulation of this storage, and its role in physiology and disease, 
are not well understood.  
1.4 The findings in “sodium storage in human tissues is mediated by 
glycosaminoglycan expression“ as base for this work 
Most recently, a human study was performed at our institute, supporting the theory that GAG 
expression mediates sodium storage in human tissues, including skin, muscles and arteries 
(Fischereder et al., 2017). The findings of this study, described in the following, gave origin to 
further questions regarding the regulation of GAG expression, which lead to the present work. In 
this study, 27 dialysis patients, mostly recipients of living kidney transplants, and 21 healthy 
transplant donors, were included. During surgery, tissue samples of abdominal skin, muscle and 
arteries were taken. The Na+ content in the tissue [Na]T was then measured by inductively coupled 
plasma-optical emission spectroscopy.  Glycosaminoglycan content was assessed in skin, muscle 
and arterial samples by standardized Alcain Blue-PAS staining (Fischereder et al., 2017). To in-
vestigate regulation of GAG-synthesis, expression of genes involved in GAG-synthesis was ana-
lyzed by RT-PCR in the respective biopsies. The data showed no difference in [Na]T between 
dialysis patients and healthy controls, thus supporting the results of previous studies (Dahlmann 
et al., 2015), but a high interindividual variability of [Na]T was seen. However, there was an in-
traindividual correlation of [Na]T found for skin, artery and muscle, significantly highest in arter-
ies and significantly lowest in muscle (Fischereder et al., 2017). Furthermore, [Na]T correlated 
significantly with glycosaminoglycan content of the tissue and with the expression of Xylosyl-
transferase 1 (XYLT1), the enzyme catalyzing the first step in biosynthesis of GAGs (Fischereder 
et al., 2017). 
 
The findings of the study support the relevance of glycosaminoglycan expression in water-free 
sodium storage in skin, muscle and arteries. Furthermore, Fischereder et al. (2017, p. 6) hypoth-
esized that glycosaminoglycan expression and [Na]T  is actively regulated, raising the question as 
to which biologic mechanisms trigger XYLT1 expression and GAG synthesis. In the in vivo study, 
the XYLT1 expression, assayed with RT-PCR, correlated with calculated osmolality and serum-
phosphate levels. However, in vitro experiments with immortalized human fibroblasts did not 
show the same correlation. On the other hand, treatment with the pleiotropic cytokine transform-
ing growth factor b (TGF-b) in vitro led to increased XYLT1 expression (Fischereder et al., 2017).  
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1.5 Biology of glycosaminoglycans  
In order to better understand how glycosaminoglycans (GAGs) may function as a potential site 
for sodium storage, it is essential to gain insight into the complex biology of GAGs, especially 
their synthesis and function. Glycosaminoglycans are linear chains of sulfated polysaccharides 
and composed of alternating copolymers of amino sugars (glucosamine that is N-acetylated, N-
sulfated or N-acetylgalactosamine) and either an uronic acid (glucorunic acid or iduronic acid) or 
galactose. GAGs are produced by virtually all mammalian cells (Lindahl et al., 2015, pp. 1-4). 
Owing to the presence of acidic sugar residues and/or sulfate groups along the GAG chains, GAGs 
possess a highly negative charge (Prydz & Dalen, 2000, p. 1). Linear sulfated GAGs are classified 
in four major subclasses based on their disaccharide composition and sulfation: Chrondroitin sul-
fate (CS), dermatan sulfate (DS), heparan sulfate (HS) and heparin (Sugahara & Kitagawa, 2000). 
The sulfated GAG chains are covalently attached to a core protein to form proteoglycans. The 
type of GAG chain that becomes attached depends on the structure of the core protein and the 
environment of the Golgi apparatus, the place where GAGs are polymerized and subsequently 
sulfated. GAG chains are linked to the respective core protein through the common GAG-protein 
Figure 2: Tissue sodium concentrations correlate with XYLT1-Expression 
Tissue sodium concentrations measured in muscles and arteries correlated with XYLT1 expression of the 
respective biopsy. Image adapted from Fischereder et al. (2017, p. 5). 
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linkage region GlcA-Gal-Gal-Xyl-O-Ser (Lindahl et al., 2015, p. 4). The biosynthesis of GAGs 
is initiated by the formation of this linkage region. The key enzyme of GAG chain initiation in 
proteoglycans is Xylosyltransferase (XYLT), which catalyzes the transfer of D-xylose from UDP-
D-xylose to specific serine residues of the core protein (Muller et al., 2005, p. 1). The activity of 
XYLT is thought to be rate-limiting, which makes it an important potential regulatory factor in 
GAG biosynthesis (Stoolmiller, Horwitz, & Dorfman, 1972, p. 8). There exist two XYLT family 
members in mammals, xylosyltranferase 1 (XYLT1) and xylosyltranferase 2 (XYLT2). XYLT1 
was shown to have enzymatic activity, while XYLT2 did not show enzymatic activity in vitro; its 
function is, for the most part, unknown (Brunner, Kolarich, Voglmeir, Paschinger, & Wilson, 
2006). However, a study in Chinese hamster ovary cells suggests a significant role for XYLT2 in 
proteoglycan biosynthesis and hypothesized that the cell type may determine which xylosyltrans-
ferase family member is utilized (Cuellar, Chuong, Hubbell, & Hinsdale, 2007, p. 5).  
 
After their synthesis, proteoglycans are transported from the Golgi apparatus to their site of func-
tion. They are the major component of the extracellular matrix, and are also found at the cell 
surface and in intracellular organelles. GAGs as part of proteoglycans are known to have diverse 
functions. They are, amongst others, involved in cell adhesion and cytokine action and play an 
important role in the control of growth and differentiation. They also provide structural integrity 
to connective tissue and cells (Kuhn et al., 2001). What makes GAGs interesting for this study, is 
their highly negative charge, which may give them the ability to incorporate Na+, by attracting 
the positively charged Na+ ions to leave their hydrated state (Titze et al., 2004).  
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Figure 3: Biosynthesis of GAGs  
Initiation of the biosynthesis of chondroitin sulfate (left chain) and heparan sulfate (right chain) by the key 
enzyme XYLT. Image adapted from Lindahl, Couchman, Kimata, and Esko (2015, p. 12).  
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1.6 Transforming growth factor β and its role in renal disease 
As transforming growth factor β (TGF-β) has been suggested to influence GAG synthesis and is 
known to play a role in kidney disease, it appears to be a relevant subject when discussing the 
potential regulation of non-osmotic sodium storage, and is addressed in more detail in the follow-
ing sections of the thesis. TGF-β and related factors are shown to be essential for the regulation 
of diverse biological processes. They play an important role during embryogenesis, in the home-
ostasis of most human tissue, regulation of immune response and wound healing. Moreover, they 
are involved in several pathologies including cancer, developmental disorders and tissue fibrosis 
(Finnson, McLean, Di Guglielmo, & Philip, 2013). Though the TGF-β superfamily is composed 
of a large number of structurally related polypeptide growth factors, this summary will focus 
solely on the TGF-β subfamily. There exist three isoforms of TGF-β in mammalian tissues, TGF-
β1, TGF-β2 and TGF-β3, which share more than 70% of sequence similarity, but are known to 
have partly different biological activities (Mittl et al., 1996). The most abundant isoform is TGF-
β1, which is ubiquitously expressed. TGF-β is synthesized as a precursor protein and secreted as 
a latent TGF-β complex, remaining inactivated in the ECM until its activation by protease, acid-
lase balance, heat, thrombospondin-1, reactive oxygen species and integrin (Khalil, 1999).  
It is well known that TGF-β contributes to pathophysiology of many renal diseases, including 
diabetic nephropathy (Ziyadeh, Sharma, Ericksen, & Wolf, 1994), functioning as a key mediator 
in the pathogenesis of renal fibrosis (J. B. Kopp et al., 1996). Once activated, TGF-β induces 
elevated production of extracellular matrix proteins, leading to conditions associated with kidney 
fibrosis, such as glomerulosclerosis and tubulointerstitial fibrosis (Loeffler & Wolf, 2014). This 
pro-fibrotic effect has also been confirmed by the findings that therapeutic targeting of TGF-β 
can reduce renal injury (Chen et al., 2003). However, the potential clinical success of these inter-
ventions is at present uncertain, as recent studies in TGF-β transgenic mice have demonstrated 
that TGF-β not only triggers renal fibrosis, but, also, when present as a latent complex, induces 
anti-inflammatory effects, and thus preventing renal inflammation (Huang, Chung, Wang, Lai, & 
Lan, 2008). An inhibition of inflammation was also associated with an increase in SMAD7, an 
inhibitory version of the SMAD transcription factor family (detailed below), that is activated by 
TGF-β signaling as negative feedback mechanism loop (Wang et al., 2005). 
These observations indicate a pleiotropic activity of TGF-β in renal disease, suggesting diverse 
roles for activated TGF-β (pro-fibrotic) and latent TGF-β (anti-inflammatory) (Sureshbabu, 
Muhsin, & Choi, 2016). The multifunctionality of TGF-β and its role in kidney disease were 
investigated further in this study. 
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1.7 Relevant signaling pathways  
 TGF-β/SMAD signaling 
Activated TGF-β exerts its biological effects, as well as its pro-fibrotic effect in renal disease, by 
activating the canonical SMAD signaling pathway (Kubiczkova, Sedlarikova, Hajek, & 
Sevcikova, 2012). Activated TGF-β binds to the transmembrane receptor TGF-β receptor type II 
and brings it together with the TGF-β receptor type I receptor, both serine/theorine kinase recep-
tors, forming a functional heterodimer. This leads to recruitment and activation of SMAD family 
transcription factors: Via the function of SMAD anchor for receptor activation (SARA) as an 
adaptor protein, phosphorylation of the intracellular regulatory R-SMAD proteins SMAD2/3 
takes place. In their phosphorylated form, R-SMAD proteins have a high affinity to bind Co-
SMADS, here SMAD4, that cooperate during signaling. The resulting complex of R-SMADs and 
Co-SMAD is then transported into the nucleus of the recipient cell to modulate gene transcription 
of  target genes (Massague, 1998).  
 
T
β
R
I
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β
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II
Signaling cell
Recipient cell
TGF-β
1/2/3
SARA
SMAD2/3 P
SMAD2/3 P
SMAD4
SMAD4
Nucleus
SMAD2/3
SMAD4
P
T
β
R
I
T
β
R
II
Figure 4: TGF-β driven SMAD activation pathway  
Binding of the activated ligands TGF-β1/2/3 to TβRII brings together TβRI and TβRII, both serine/threo-
nine protein kinases. One of these kinases phosphorylates the other, which in turn triggers the phosphory-
lation of the R-SMADS SMAD2/3. Phosphorylated R-SMADS bind to co-SMAD4 and the complex is 
transported into the nucleus where it regulates gene expression. TβRI= TGF-β type II receptor, TβRII= 
TGFβ type II receptor, SARA= SMAD anchor for receptor activation, P= phosphorylation. 
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TGF-β signaling leads to activation of inhibitory SMADs (I-SMADS), e.g. SMAD7, which func-
tion in a negative feedback loop. Importantly, a number of non-canonical TGF-β pathways have 
been identified, which may function independently of SMAD (Derynck & Zhang, 2003).  The 
factors driving noncanonical activation of the pathway are not well characterized. 
 Hyperosmotic stress and NFAT5-mediated osmotic response activation 
As steady state XYLT1 mRNA expression was shown to correlate with the calculated osmolality 
in vivo (refer to 1.4), biologic mechanisms involved in the osmotic stress response will be ad-
dressed in this, and following paragraphs, as they may be relevant for regulation of sodium stor-
age. Elevation of extracellular sodium levels leads to hyperosmotic stress and can be harmful to 
cells. It can result in cell deformation, a disturbance in cellular function and inhibition of cellular 
proliferation. The Nuclear Factor of Activated T Cells- 5 (NFAT5), also known as tonicity en-
hancer binding protein (TonEBP), is a transcription factor that protects mammalian cells from 
hyper-osmotic stress by stimulating the transcription of osmoprotective genes (Miyakawa, Woo, 
Dahl, Handler, & Kwon, 1999). NFAT5 is the latest member of the so called Rel family of tran-
scription factors, which in addition to NFAT5, includes the other Nuclear Factors of Activated T 
cells (NFAT) 1-4 and Nf-kB. Although the NFAT proteins share a similar structure, NFAT5 dif-
fers greatly from the other NFAT proteins: It does not possess a calcineurin binding domain, as 
the proteins NFAT1-4 do, but instead is highly sensitive for NaCl-induced hypertonicity 
(Aramburu et al., 2006). Various studies showed that NFAT5 has an important osmoprotective 
function in the kidney, where cells are physiologically exposed to hyperosmolarity, thus ensuring 
proper function of the renal medulla during antidiuresis (Christoph, Beck, & Neuhofer, 2007). 
However, its function is not limited to the renal medulla, since NFAT5 is expressed in virtually 
all tissues, and plays an important role for these tissues to survive and function properly in hyper-
tonic environments (Trama, Lu, Hawley, & Ho, 2000). Although the exact molecular events lead-
ing to regulation of NFAT5 in response to hyper-osmotic stress are not fully understood, more 
than a dozen protein and lipid kinases have been identified in this context (Zhou, 2016). The 
following mechanism has been suggested to describe NFAT5 activation: The Guanine Nucleotide 
Exchange Factor Brx, located near the plasma membrane, responds to osmotic stress with activa-
tion of Rho-type small G-proteins and stimulates the MAPK cascade by interacting with c-Jun N-
terminal kinase-interacting protein-4 (JIP4), a p38 MAPK-specific scaffold protein. Then, a com-
plex of JIP4 with downstream kinases MKK3 and MKK6 is formed, which leads to activation of 
p38 mitogen-activated protein kinases (p38 MAPK), which in turn stimulate the transcription 
factor NFAT5 (Kino et al., 2009). Subsequently, NFAT5 induces osmoprotective gene products, 
that allow cells to adapt to the hypertonic environment.  
 
1 Introduction 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition to its well-known osmoprotective function, NFAT5 also regulates genes that are not 
obviously associated with hypertonic stress  (Neuhofer, 2010, p. 2). Amongst others, the induction 
of NFAT5 in macrophages of the skin was shown to induce the expression of the vascular endo-
thelial growth factor C (VEGF-C), leading to increased lymphangiogenesis (Jantsch, Binger, 
Muller, & Titze, 2014). Interestingly, NFAT5 induction was also shown to positively regulate β-
1,3 Glucuronosyltransferase-I (GlcAT-I), an enzyme important in glycosaminoglycan synthesis, 
in nucleus pulposus cells (Hiyama et al., 2009). These findings suggest biological importance of 
NFAT5 beyond its function in osmoprotection.  
Brx G-protein
JIP4
p38p38 MAPK
Plasma membrane
NFAT5
MKK 3
MKK 6
Osmotic stress
Activation of Osmotic stress response
Figure 5: NFAT5 mediated osmotic response activation 
Hyperosmolar environment leads to a physical interaction between Brx and JIP4 and the activation of Rho 
type small G-proteins. A complex of JIP4 and the downstream kinases MKK3 and MKK6 activates p38 
MAPK, which in turn induces NFAT5 expression leading to activation of osmotic stress response. BRx= 
Guanine Nucleotide Exchange Factor Brx, JIP4= c-Jun N-terminal kinase-interacting protein-4, p38 
MAPK= p38 mitogen-activated-protein kinases, NFAT5= Nuclear Factor of Activated T Cells-5. 
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1.8 Endocrine regulators in sodium and mineral homeostasis  
As stated above, various mechanisms involved in the osmotic stress response may have an effect 
on the regulation of sodium storage through their influence on GAG synthesis. A selection of 
endocrine regulators in sodium and mineral homeostasis are discussed below.   
 Arginine vasopressin (AVP) 
Arginine vasopressin (AVP), also termed antidiuretic hormone (ADH), is an important mediator 
linked to maintaining the stability of the body fluid osmolality, in addition to other physiological 
functions. It is synthesized as a prohormone in the hypothalamus and stored in the posterior pitu-
itary gland. AVP is released from the pituitary gland as a physiological response to increased 
plasma osmolality or hypovolemia (Kam, Williams, & Yoong, 2004). Once secreted, it has a 
strong antidiuretic effect in the kidney by acting through the renal vasopressin receptor V2 in cells 
of the collecting duct, leading to mobilization of aquaporin water channels, and thus increased 
water reabsorption. As a reasonable complimentary effect, AVP has vasoconstrictive effects me-
diated by vasopressin receptor V1 in vascular smooth muscle (Barberis, Mouillac, & Durroux, 
1998), which helps to maintain blood pressure in situations with hypovolemia. Vasopressin re-
ceptor V1 is also expressed in cardiac myocytes, brain, testis, liver and renal medulla. Addition-
ally, vasopressin promotes ACTH release by binding to the pituitary receptors V3 and may play 
a role in central control of circadian rhythm and thermoregulation (Mieda et al., 2015). 
 Endothelin 
Endothelin is a cell derived peptide that functions as the most powerful vasoconstrictor known.  
There exist three isoforms in mammalian cells, ET-1, ET-2 and ET-3, though this summary will 
focus on Endothelin-1 (ET-1), which is produced in vascular endothelium as well as renal epithe-
lial cells (Kohan, Inscho, Wesson, & Pollock, 2011). It was shown that ET-1 is involved in the 
regulation of arterial pressure and in Na+ homeostasis during conditions of elevated salt intake 
(Pollock & Pollock, 2001), most likely through controlling salt handling within the kidney. Fur-
thermore, recent data showed that ET-1 leads to facilitation of Na+ movement through the skin 
interstitium during sodium loading (Speed et al., 2015, pp. 5-6).   
 Fibroblast growth factor 23  
The protein fibroblast growth factor 23 (FGF23) is a member of the fibroblast growth factor (FGF) 
family and plays an important role in phosphate and vitamin D homeostasis (Kiela & Ghishan, 
2009, pp. 3-4). It is produced in bone and its primary physiological function is associated with 
stimulation of urinary phosphate excretion in the kidneys, and reduction of circulating calcitriol 
concentrations in response to high phosphate (Fukagawa, Nii-Kono, & Kazama, 2005). The phys-
iological action of FGF23 signaling in renal cells is suggested to function as follows: FGF23 binds 
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to FGF receptors (FGFR), with a protein termed Klotho serving as essential cofactor to enhance 
its affinity to the FGFR (Urakawa et al., 2006). Activation of the receptor leads to inhibition of 
renal phosphate reabsorption by reduction of renal mRNA and protein levels for the type IIa so-
dium-phosphate cotransporter (NaPi-2a) in the proximal tubular epithelium (Shimada et al., 
2004). In chronic kidney disease (CKD), circulating FGF23 was shown to rise dramatically with 
a decline in renal function (Wolf, 2012). Recent studies suggest that a deficiency of Klotho rep-
resents one of the pathological mechanisms in chronic renal disorders (Olauson & Larsson, 2013), 
eventually leading to a switch in FGF23 induced signaling in cells with a lack of Klotho, but 
instead with the fibroblast growth factor receptor 4 (FGFR4) present. Klotho-independent activa-
tion of FGFR4 has been shown to lead to hypertrophy and fibrosis in cardiac myocytes  (Grabner 
et al., 2015, pp. 3-5).  
1.9 Rationale of this study 
Since tissue sodium concentrations were shown to correlate in vivo with glycosaminoglycan con-
tent, and the steady state expression of XYLT1 mRNA encoding the enzyme that initiates GAG 
synthesis concentrations, the goal of this study was to investigate the potential regulation of 
XYLT1 expression, in the context of sodium biology, in order to gain further insight into regula-
tory mechanisms of tissue sodium storage. For this purpose, an in vitro cell culture system with 
pathway specific reporter constructs was to be established, to serve as a tool for internal control 
of successful stimulation of their respective intracellular pathways independently of the resulting 
effect on XYLT1 expression. K4IM cells, SV40 large T antigen immortalized human dermal fi-
broblasts, were used as a model for tissue fibroblasts and HEK 293 cells were used as model for 
parenchymal renal cells. We sought to determine if XYLT1 expression would be actively modu-
lated in our in vitro systems by treatment with the following external stimuli: 
1) Hyperosmotic environment. Intuitively, high extracellular sodium concentrations could 
be thought to stimulate non-osmotic sodium storage as a compensation mechanism. 
XYLT1 was also shown to correlate with calculated osmolality in vivo.  
2) Vasopressin, as its main role is to maintain the stability of the body fluid osmolality and 
is increased with raising osmolality. 
3) Endothelin 1 is shown to be involved in Na+ homeostasis during conditions of elevated 
salt intake. 
4) FGF23 functions as an important mediator in phosphate homeostasis via sodium-depend-
ent phosphate transport and is known to increase under decreasing kidney function. 
5) TGF-β, as amongst its numerous functions, it has been suggested to influence GAG syn-
thesis and is known to play a role in progression of kidney disease.  
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2 Material and methods 
2.1 Material 
 Cell culture  
2.1.1.1 Cells 
Table  1: Cells 
Cell line Medium Origin 
K4IM cells, human fibroblast 
cell line immortalized with 
SV40 T Antigen  
DMEM with 10% FCS and 
1% PS 
The cell line was a gift from 
Prof. Haas, Freiburg (Ger-
many) 
HEK293 cells, adherent hu-
man embryonic kidney cell 
line 
DMEM with 10% FCS and 
1% PS 
ATCC CRL-1573 Manassas, 
Virginia (USA) 
 
2.1.1.2 Media and supplements 
Table  2: Cell culture media and supplements 
 
Name Manufacturer 
Blasticidin S HChl, 10 mg/ml Life technologiesTM, Carlsbad (USA) 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt (Germany) 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
Life technologiesTM, Carlsbad (USA) 
Dulbecco’s Phosphate Buffered Saline 
(DPBS) 
Pan Biotech GmbH, Aidenbach (Germany) 
Fetal calf serum (FCS) Biochrom GmbH, Berlin (Germany) 
Penicillin/Streptomycin (P/S) Biochrom GmbH, Berlin (Germany) 
Trypsin/EDTA Pan-Biotech GmbH, Aidenbach (Germany) 
Trypan Blue 0.4% Solution  Lonza AG, Basel (Switzerland) 
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 Bacteria 
One Shot® Mach1™ T1 Phage-Resistant Chemically Competent E. coli, InvitrogenTm, Carlsbad 
(USA). 
  Buffers and solutions 
2.1.3.1 Molecular biology 
Table  3: Buffers and solutions molecular biology 
Name Manufacturer 
1kb DNA ladder Thermo Fisher Scientific, Waltham (USA) 
Basic Nucleofector Solution for Mammalian 
Fibroblasts 
Lonza AG, Basel (Switzerland) 
Buffers for DNA restriction enzymes   NEB, Ipswich (USA) 
Buffer TE, endotoxin-free Quiagen, Hilden (Germany) 
dATP 
dCTP 
dGTP 
dTTP  
FermentasTM, Waltham (USA) 
FermentasTM, Waltham (USA) 
FermentasTM, Waltham (USA) 
FermentasTM, Waltham (USA) 
Loading buffer for agarose gels: 
0.25% Bromphenol blue 
0.25% Xylen Cyanol FF 
30% Glycerol 
 
Roth, Karlsruhe (Germany) 
Merck, Darmstadt (Germany) 
Roth, Karlsruhe (Germany) 
T4 DNA ligase buffer Neb, Ipswich (USA) 
Tris-borate-EDTA (TBE) buffer solution: 
90 mM Tris 
2mM borid acid 0.01M 
EDTA, ph 8.0 
 
Roth, Karlsruhe (Germany) 
Merck, Darmstadt (Germany) 
Roth, Karlsruhe (Germany) 
          
2.1.3.2 qPCR 
Table  4: Buffers and solutions qPCR 
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Name Manufacturer 
Acrylamid Amnion Biosciences, Bangalore (India) 
DTT InvitrogenTM, Carlsbad  (USA) 
dNTP Set FermentasTM, Waltham (USA) 
First strand buffer InvitrogenTM, Carlsbad (USA) 
Hexanucleotide Mix, 10 x conc. Roche AG, Basel (Switzerland) 
SYBR green master mix per 500µl: 
100µl 10x Taq Buffer 
7.5 µ dNTP 25 mM 
20 µl Rox reference dye 
200 µl PCR Optimizer LC120-0001 1ml 
10 µl BSA PCR grade 
2 µl SYBR green I 1:100, in 20% DMSO-H20 
120 µl MgCl2 25mM  
40.5 µl Aqua ad injectabilia 
 
FermentasTM, Waltham (USA) 
FermentasTM, Waltham (USA) 
InvitrogenTM, Carlsbad (USA) 
Bitop, Witten (Germany)  
FermentasTm, Waltham (USA) 
Sigma Aldrich, St. Louis (USA) 
FermentasTm, Waltham (USA) 
Braun, Melsungen (Germany) 
 
2.1.3.3 Microbiology media and solutions 
Table  5: Microbiology media and solutions 
Name Content 
Ampicillin Stock solution 50 mg/ml Ampicillin, 70% Ethanol, 30% H20  
LB medium per liter 10 g Bacto Tryptone, 10 g NaCl, Yeast Extract 
LB Agar plates per liter 15 g Bacto Agar, 5g Bacto Yeast Extract, 10 NaCl, 10 g Bacto 
Tryptone 
SOC medium 
 
20 g Bacto Tryptone, 2.5 mM KCL, 5 g Yeast Extract, 10mM 
NaCl, 10 mM MgCl, 10 mM MgSO4, 20 mM Glucose 
 
 Chemicals 
Table  6: Chemicals 
Name Manufacturer 
Agarose ultrapure  Thermo Fisher Scientific, Waltham (USA) 
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Aqua ad injectabilia Braun, Melsungen (Germany) 
β- Mercaptoethanol Roth, Karlsruhe (Germany) 
Ethanol, absolute  Merck, Darmstadt (Germany) 
Ethidiumbromid 1% Merck, Darmstadt (Germany) 
Sodium chloride Sigma Aldrich, Taufkirchen (Germany) 
RNAse free water InvitrogenTM, Carlsbad (USA) 
 
 Enzymes 
Table  7: Enzymes 
 
 Recombinant proteins 
Table  8: Recombinant proteins 
Name Manufacturer 
[Arg8]Vasopressin acetate salt                                       Sigma-Aldrich, Saint Louis (USA) 
FGF-23 human, recombinant, expressed in 
E.Coli   
Sigma-Aldrich, Saint Louis (USA) 
TGFb-1, recombinant, source HEK293 cells       Acris Antibodies, Inc, San Diego (USA) 
TGFb-3, recombinant, expressed in E.coli Sigma-Aldrich, Saint Louis (USA) 
Endothelin-1 (human, porcine) Tocris, Bioscience, Bristol (England) 
 
Enzyme Manufacturer 
Antarctic Phosphatase NEB, Ipswich (USA) 
DNAse I Quiagen, Hilden (Germany) 
Phusion DNA Polymerase NEB, Ipswich (USA) 
Restriction enzymes NEB, Ipswich (USA) 
SuperScript II Reverse Transcriptase InvitrogenTM, Carlsbad (USA) 
T4 DNA Ligase NEB, Ipswich (USA) 
Taq DNA-Polymerase NEB Ipswich (USA) 
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 Primer sequences qPCR 
Table  9: Primer qPCR 
Primer Sequence 5’-3’ Characteristics Manufacturer 
18s_FW 
18s_RV 
GCAATTATTCCCCATGAACG 
AGGGCCTCACTAAACCATCC 
20 bp, Tm 55°C 
20 bp, Tm 59°C 
 
Metabion inter-
national AG, 
Martinsried 
(Germany) 
CHSY1_FW 
CHSY1_RV 
TGTACACCACCCATGAGGAC  
ACCCCTTTTTGTTCTGCTCG 
20 bp, Tm 61.5 °C,  
20 bp, Tm 59.2 °C, 
cDNA specific 
InvitrogenTM 
Custom Pri-
mers, Carlsbad 
(USA)  
CHPF2_FW 
CHPF2_RV 
GACGCTGCCTCATTGACTCT 
CCCTATTTTTGGCCAGTTCA 
20 bp, Tm 62.8°C,  
20 bp, Tm 60.5 °C, 
not cDNA specific 
InvitrogenTM 
Custom Pri-
mers, Carlsbad 
(USA) 
TGFB_FW 
TGFB_RV 
CAGCACGTGGAGCTGTACC 
AAGATAACCACTCTGGCGAGTC 
19 bp, Tm 62°C 
22 bp Tm 62°C 
Metabion inter-
national AG, 
Martinried 
(Germany) 
XYLT1_FW 
XYLT1_ RV 
CTCTGGATCCACACCCAAGT  
TTGCTGTCTGTTCGCACTTT  
20 bp, Tm 59.1 °C,  
20 bp, Tm 58.6 °C, 
cDNA specific 
InvitrogenTM 
Custom Pri-
mers, Carlsbad 
(USA) 
 
 Plasmids  
Table  10: Plasmids 
Plasmid Source 
pcDNA-Gluc3-CMVMin  C. Jäckel  
pCMV (CAT) T7- SB100 The plasmid was a gift from Zsuzsanna Izsvak 
(Addgen plasmid #34879) 
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 Kit systems 
Table  11: Kit systems 
 
 Consumables 
Table  12: Consumables 
Name Manufacturer 
Cell culture flasks TPP, Trasadingen (Switzerland) 
Cell culture plates TPP, Trasadingen (Switzerland) 
Centrifuge tubes 15 ml BD Biosciences, Franklin Lankes (USA) 
Cryotubes Alpha Laboratories, Eastleigh (England) 
Tubes, 5 ml 75x12mm, PS (Luminometer) Sarstedt, Nürnbrecht (Germany) 
qPCR multiwell plates Sarstedt, Nürnbrecht (Germany) 
 
 Equipment 
Table  13: Equipment 
Name Manufacturer 
CO2 incubator New BrunswickTM Galaxy® 48 Eppendorf, Hamburg (Germany) 
LightCycler® 480 Instrument  Roche AG, Basel (Switzerland) 
Microscope  Leika microsystems, Wetzlar (Germany) 
Nano Drop ND-1000 Spectrophotometer PEQLAB Biotechnologie GmbH, Erlangen 
(Germany) 
NucleofectorTM 2b Device Lonza AG, Basel (Switzerland) 
Name Manufacturer 
BioLux Gaussia Luciferase Assay Kit NEB, Ipswich (USA) 
Endofree Plasmid Maxi Kit Quiagen, Hilden (Germany) 
Innuprep Plasmid Mini Kit Analytik, Jena (Germany) 
Pure Link RNA Mini Kit InvitrogenTM, Carlsbad (USA) 
QIAquick Gel extraction Kit Quiagen, Hilden (Germany) 
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PCR machine Mastercycler pro Eppendorf, Hamburg (Germany) 
Photometer Lumat 9507 Berthold, Bad Wildbad (Germany) 
Thermoblock, Thermomix comfort Eppendorf AG, Hamburg (Germany) 
 
 Software 
Table  14: Software 
Name Manufacturer 
Clone Manager Professional 9.2 Sci-Ed, Denver (USA) 
GraphPad Prism 7 GraphPad Software Inc. San Diego (USA) 
Lightcycler ® 480 software, 1.5.0.39 Roche AG, Basel (Switzerland) 
 
2.2 Methods 
 Cell culture 
2.2.1.1 General cell culture 
The K4IM cells and HEK293 cells were incubated at 37°C and 5% CO2 in a suitable vessel with 
DMEM medium with 10% Fetal calf serum (FCS) and 1% Penicillin/Streptomycin (PS). To pre-
vent contamination, all cell culture work was performed in a laminar flow hood. All reagents were 
warmed to 37°C in a water bath before use. Furthermore, for subculturing, the medium was re-
moved and adherent cells were washed with Dulbecco’s Phosphate Buffered Saline (DPBS) and 
detached with Trypsin-EDTA solution. When the detachment of the cells was visible under mi-
croscope, an equal volume of medium containing 10% FCS was added to stop the reaction. Sub-
sequently, the cells were pelleted by centrifugation at 220 xg (rt) for 3 minutes. After resuspend-
ing the cell pellet in fresh medium, a fraction of the culture medium according to the desired split 
factor was seeded into a new cell culture flask and fresh medium was added. 
2.2.1.2 Counting cells 
Cells/ml were counted by using a Neubauer chamber. A sample was prepared by mixing an ali-
quot of the cell suspension 1:2-1:5 (depending on celldensity) with trypan blue solution (0.4%) 
to differentiate viable from dead cells. Subsequently, 10 µl of the mixture was pipetted into the 
counting chamber. Under the microscope, the living cells were counted in all four quadrants of 
the chamber. The number of cells/ml was calculated as follows:  
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!"#$%	"'	()**+
$#,-).	"'	/#01.0$%+ ∗ the dilution factor ∗ 10
4 = number of cells/ml 
2.2.1.3 Freezing and thawing cells 
Cells were frozen in cryotubes to minimize genetic change and avoid contamination. Freezing 
medium contained the respective culture medium of the cells +10% Dimethyl sulfoxide (DMSO). 
The tubes were stored at -80°C freezer over 24h prior to transferring them into a tank with liquid 
nitrogen for long time storage. The frozen cells were thawed in a 37°C water bath and rapidly 
transferred into a cell culture flask with prewarmed medium to dilute DMSO to non-toxic con-
centration. After 24h, the medium was exchanged to remove DMSO completely.   
 Molecular biology 
2.2.2.1 Polymerase chain reaction (PCR) 
PCR is a method to amplify a selected DNA sequence using a heat-stable DNA polymerase. A 
repetitive amplification allows the synthesis of millions of copies in short time. In each cycle, the 
amount of the selected DNA doubles, which leads to an exponential increase. Nucleotide se-
quences of the flanking region of the target DNA were used to select suitable primers. The primers 
were provided by Invitrogen LifeTechnologies.   
Per tube (25 µl), the following standard mix was prepared: 5x Reaction buffer (1:5), template 
DNA (500 ng), fw primer (400 nM), rv primer (400 nM), dNTPs (200 nM), Polymerase (4.5 
units), H20 (up to 225 µl). All polymerase chain reactions were performed after the following 
protocol: 
Table  15: General PCR protocol 
Step Settings Cycle count 
Initial denaturation  98°C, for 3 min.  1 
Denaturation  98°C, for 30 sec 30 
Annealing of primers and 
DNA 
Temperature depends on the primer, for 
30 sec 
30 
Chain extension 72°C, time depends on size of the product  30 
Final extension 72°C for 10 min 1 
Final hold 10°C 1 
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After separation of the double stranded target DNA into single strands, so called denaturation, the 
separated strands were cooled for annealing of the primers. The annealing temperature was set up 
individually for each PCR, depending on the primers. In the next step, complementary copies of 
the target were produced by the DNA polymerase. After completion of one cycle of replication, 
the reaction mixture was heated up again. After binding of each DNA strand to a complementary 
primer, the cycle of chain extension was repeated. In total, 30 cycles were performed before final 
extension. 
After completion of the PCR, agarose gel electrophoresis was used for analysis and purification 
of the resulting products. 
2.2.2.2  Agarose gel electrophoresis 
Agarose gel electrophoresis is a common method to separate DNA fragments or proteins using 
agarose as a matrix. The DNA fragments were separated and DNA was visualized using ethidium 
bromide, a DNA intercalating agent that fluoresces under UV light. The percentage of agarose in 
the agarose gel was chosen after the expected size of the DNA fragments; 2% for smaller frag-
ments consisting of <800 base pairs (bp) and 0.6% for larger fragments consisting of >1000 bp. 
For preparation of the gel, the agarose powder was dissolved in Tris-borate-EDTA (TBE) buffer 
with added ethidium bromide, and heated to near-boiling point in a microwave before it was 
casted in the gel chambers. Loading buffer for agarose gels (6x) was mixed with the DNA samples 
and a size standard. Subsequently, the mixture was pipetted into the wells. During the electropho-
resis, which was performed at 120 V, the gel was completely submerged in TBE buffer. Then, the 
DNA was visualized under UV light and the gels were photographed for documentation. In case 
of further use of the separated DNA fragments, the DNA bands were cut out of the gel under UV 
light. For subsequent DNA extraction from the gel, Qiagen gel Extraction Kit was used according 
to the manufacturer’s instructions. 
2.2.2.3 Sequencing of DNA  
For sequencing, the samples were sent to GATC Biotech company.  
2.2.2.4 Measurement of DNA concentration  
A nanodrop spectrophotometer was used, according to the manufacturer’s instructions to measure 
the amount of DNA in a solution. After initializing the nanodrop with 2 µl RNase free water, the 
measurements were made from 2 µl of each sample. 
2.2.2.5 DNA restriction digestion  
To identify suitable restriction enzymes to cut the plasmids within a specific restriction site, 
CloneManager Software was used. For the digestion mix, the following rule was respected: For 
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digestion of 1 µg DNA, 1 unit of enzyme was added per hour, up to a maximum of 10% of the 
total volume. The buffer found to be most compatible with the enzymes was used according to 
the suggestion of the manufacturer. Typical protocol (mixed in a microfuge tube): 1 µl 10x buffer, 
5.7 µl H20, 3µl DNA (100ng/µl), 0.3 µl enzyme. After brief vortexing and centrifugation, the 
mixture was incubated for 1h at a suitable temperature (37°C-65°C). 
2.2.2.6 End modification: Dephosphorylation  
In order to prevent re-ligation of vectors, the 5’phosphate group was removed after digesting 
DNA with the Antarctic phosphatase according to the manufacturer’s instructions. It was then 
purified using a commercially available kit.  
2.2.2.7 Ligation of DNA fragments 
To insert the DNA of interest into a vector backbone, T4 DNA ligase enzyme was used according 
to the manufacturer’s instructions. Molar ratio 1:3 vector to insert. T4 DNA ligase was added last. 
20µl reaction: 2µl T4 DNA ligase buffer 10x, vector DNA (4kb) 50 ng, insert DNA (1 kb) 37.5 
ng, T4 DNA Ligase 1 µl. Nuclease-free water to 20 µl.  
2.2.2.8 Transformation of competent E. coli Mach 1 
The process of transformation was used to introduce the plasmid of interest into chemically com-
petent E. coli bacteria. The bacteria carrying the plasmid were grown up and selected by antibi-
otics. For the transformation, frozen E. coli Mach-1 bacteria stored at -80°C were rapidly thawed 
on ice. 10-100 ng of DNA was added to 50µl of the bacteria suspension in a tube. After mixing 
gently, the mixture was incubated for 5 to 30 min on ice and subsequently heat shocked at 42°C 
for 45 seconds before transferring it back on ice for cooling. 250 µl SOC medium was added, 
followed by a 60 min incubation at 37°C and 500 rpm. Then, the mixture was plated onto pre-
warmed agar plates with an appropriate selective antibiotic for subsequent incubation over night 
at 37° C. Concentration of selective antibiotics: Kanamycin 50 µg/ml, Ampicillin 120 µg/ml. 
2.2.2.9  Isolation and analysis of plasmid DNA from transformed E. coli bacteria 
Single colonies from the agar plates or the backup plate were transferred into liquid cultures (LB-
medium containing the selection antibiotic). The liquid cultures were then incubated overnight on 
a warmed shaking device (300 rpm). Commercially available kits were used for isolation accord-
ing to the manufacturer’s instructions (Innuprep Plasmid Mini kit for liquid culture up to 5 ml, 
Quiagen Endofree plasmid max kit for liquid cultures up to 100 ml). The plasmid DNA extracted 
by minipreparation was used to analyze the clones. The DNA was digested using appropriate 
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restriction enzymes and the resulting fragments were then analyzed by agarose gel electrophore-
sis. Maxipreparation was performed to gain up to 300-500 µg of purified DNA for further use. 
DNA-concentration was measured using the nanodrop photometer (see 2.2.2.4). 
 Cloning strategies  
The tools present in our laboratory were used. Cloning of the vectors was mainly conducted by 
Carsten Jäckel and Nadja Ehni. 
2.2.3.1 Traditional cloning strategy 
The plasmids were cloned using traditional cloning. Restriction enzyme cloning and T4 DNA 
Ligase were used for the modification steps in the vectors backbones described in 2.2.3.2. accord-
ing to the manufacturer’s instructions (Jackel et al., 2016, p. 2). 
2.2.3.2 Design of pcDNA-Gluc3-Promotor vector 
To monitor the activation status of regulatory pathways, a reporter vector system was designed in 
our laboratory by Carsten Jäckel (Jackel et al., 2016). For this purpose, the commercially available 
pcDNA6/TR TET Repressor expression vector (Thermo Fisher Scientific, Walham, USA) was 
modified in multiple ways (Jackel et al., 2016, p. 2). First, inverted terminal repeats compatible 
for SB100 transposase (SB ITRs) were introduced, allowing stable integration of transgenes into 
cell genomes by an active mechanism (Jackel et al., 2016, p. 2). Then, a modified Gaussia Lucif-
erase reporter cassette based on the commercially available pGL3-Promoter Vector (Promega, 
Fitchburg, USA) was inserted, that contains Gaussia princeps instead of Firefly luciferase and a 
cytomegalovirus promoter replacing the SV40 minimal promoter for less background activity 
(Jackel et al., 2016, p. 2). The function of the TET-Repressor was retained. The resulting vector, 
which in this work is named pcDNA-GLuc3-CMVMin Vector, was published by Jackel et al. 
(2016) under the name pSBTET.reporter. 
 
 
 
 
 
 
 
 
2 Material and methods 24 
 
 
 
 
2.2.3.2.1 Sleeping Beauty transposon system 
Delivery of DNA molecules into mammalian cells is often inefficient and the expression of the 
transgene is brief due to intracellular breakdown. To optimize the potential for the generation of 
stable transfectants, Sleeping beauty (SB) transposon system was used. It is a non-viral vector 
system allowing for the efficient stable integration of transgenes into genomes by an active mech-
anism. The gene of interest is flanked by SB-transposon inverted terminal repeats (ITR). The SB 
transposase compatible reporter is cotransfected into cells with a plasmid carrying the transposase 
enzyme gene. The SB transposase can so bind to the ITR and cuts the transposon out of the plas-
mid to insert it into a new DNA locus.  
CMV
Am
p
R
EP
O
R
TE
R
SB
SB
PolyA
Figure 6: pcDNA-GLuc3-CMVMin  
SB= Sleeping beauty transposon inverted terminal/direct repeats. CMV= Cytomegalovirus Promoter, TetR: 
TetRepressor. Poly   A= polyadenylation signal sequence. MP= minimal promoter. RE= transcription re-
sponsive elements. Gaussia Luc= CDS of the Gaussia luciferase. F1 ori= origin of replication. SV40= SV40 
Promoter. Blasti= Blasticidin resistance gene. Amp= Ampicillin resistance gene for bacterial selection.  
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2.2.3.2.2 Gaussia Luciferase reporter protein 
The pcDNA-GLuc3-CMVMin Vector uses Gaussia Luciferase (GLuc) as reporter protein, a nat-
urally secreted protein by the copepod, Gaussia princeps, that catalyses the oxidation of the sub-
strate coelenterazine in a reaction that emits light. The amount of light can be measured directly 
from the supernatant of the cells without cell lysis. To perform luciferase reporter assays of a gene 
of interest, the transcription factor responsive elements (RE) associated to that gene have to be 
introduced into the vector’s backbone. These responsive elements function then together with a 
minimal promoter element to modulate the activity of the luciferase reporter gene.  
 
 
 
 
 
 
 
 
 
 
 
2.2.3.3 Introduction of responsive elements into pcDNA-Gluc3-CMVMin Vector 
For the generation of specific reporter vectors, designed multimers of bindings sites for pathway-
associated transcription factors were ligated into the pcDNA-Gluc3-Promotor vector backbone 
by Pstl and Xhol digests (Jackel et al., 2016, p. 2).  
2.2.3.3.1 TGF-b/SMAD reporter 
This TGF-b/SMAD reporter is a reporter for TGF-b/SMAD-based signaling. The amount of TGF-
b dependent reporter expression in the stably transfected cells can be measured by assaying the 
Gaussia Luciferase activity that is secreted into the growth media. A series of SMAD consensus 
mCMV
++
TF
RE
Gaussia
Luciferase
reporterRE RE
Figure 7: Modulation of the Gaussia luciferase reporter activity  
The transcription factor binds to the transcription-response-element whereby the Cytomegalovirus-pro-
moter activity gets enhanced, subsequently leading to increased Luciferase activity. The produced lumi-
nescence can be measured in the supernatant of the cells. It increases proportional to the amount of 
enzyme, which in turn, reflects the level of transcription. TF= transcription factor, RE= transcription-
response-element, mCMV= minimal Cytomegalovirus-promoter. 
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binding elements are located in front of a minimal CMV promoter. The system consists of eleven 
SMAD binding elements (5x multimer): AGCCAGACAGT. It was ordered synthetically and  
then ligated  between the Xhol and Pst I sites of the pcDNA-Gluc-CMVMin backbone (Jackel et 
al., 2016). The resulting vector is here named pcDNA-Gluc3-CMVMin-TGFv2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3.3.2 NFAT5 reporter 
The NFAT5 reporter is a reporter for activation of the NFAT5 signaling pathway, that is involved 
in the activation of a response to hyperosmotic stress. A series of NFAT5 binding elements are 
located in front of a minimal CMV promoter. The reporter consists of the dimer CAGCGG-
TAATTTTCCACCA, synthetically produced and ordered from a manufacturer for this purpose. 
The binding element was ligated  between the Xhol and Pst I sites of the pcDNA-Gluc-CMVMin 
backbone (Jackel et al., 2016). The resulting vector is here named pcDNA-Gluc3-CMVMin-
NFAT5. 
CMV
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pcDNA-GLuc3-CMV Min-TGFv2
8428 bp
Figure 8: TGF-b/SMAD reporter 
The SMAD element was ligated into the backbone of the pcDNA-Gluc-CMVMin-Vector. 
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 In vitro experiments 
2.2.4.1 Stable transfection of cells using nucleofection and Sleeping Beauty transposase 
Transfection describes the process of adding foreign DNA into eukaryotic cells. There exist var-
ious transfection methods. Here, nucleofector technology (Lonza, Basel, Switzerland) was used 
to transfect plasmid DNA into the human dermal fibroblast cell line K4IM. This technology is 
based on electroporation and uses cell-type specific Nucleofector solution. By a device called 
Nucleofector, an electric pulse is generated and leads to an increase of the cell membrane perme-
ability. This allows the foreign DNA in the medium to enter the nucleus of the cells.  
For stable integration, reporter plasmids were cotransfected with pCMV (CAT) T7 SB 100 trans-
posase expression plasmid (see 2.2.3.2.1). 
The fibroblast cell culture and the transfection procedure were performed according to the Amaxa 
Nucleofector protocol for Primary Mammalian Fibroblasts, as follows: Cells were subcultured 2-
CMV
Am
p
SB
SB
PolyA
pcDNA-GLuc3-CMV Min-NFAT5
8446 bp
NFAT5
REPORTER
Figure 9: NFAT5 reporter  
The NFAT5 element was ligated into the backbone of the pcDNA-Gluc-CMVMin-Vector. 
 
 
2 Material and methods 28 
 
4 days before nucleofection. When 70-90% confluent, the cells were detached and counted; the 
amount of 1*106 cells per nucleofection sample was needed. After transferring the cells into a 1.5 
ml centrifuge tube, the tube was centrifuged at 7000 xg for 1 min and the cell pellet was resus-
pended carefully in 100 µl room temperature Nucleofector Solution per sample. 100 µl of the cell 
suspension was then combined with 0.5 µg of the desired plasmid DNA and 1.5 µg 
pCMV(CAT)T7 SB 100. Subsequently, the cell/DNA suspension was transferred into a certified 
cuvette, avoiding air bubbles, and closed with a cap. After inserting the cuvette into the Nu-
cleofector device, the nucleofection was performed using the 3T3 L1 pre ad (ATCCC) Nu-
cleofector program.  The cuvette suspension was then carefully transferred into a 25 cm2 flask 
with 5 ml medium. After incubation at 37°C for 24 hours, the medium was removed and medium 
containing the selective antibiotic was added to start selection.  
For transfection of the plasmids into Hek293 cells, the transfection procedure was performed ac-
cording to the Amaxa Nucleofector protocol provided for HEK-293.  
 
Table  16: Generation of reporter cell lines 
Cell line Reporter construct Resulting reporter cell line 
K4IM cell line pcDNA-Gluc3-CMVMin-TGFv2 TGF-b/SMAD reporter K4IM cells 
 pcDNA-Gluc3-CMVMin-NFAT5 
 
NFAT5 reporter K4IM cells 
Hek293 cell line pcDNA-Gluc3-CMVMin-TGFv2 TGF-b/SMAD reporter HEK293 cells 
 
 
2.2.4.2 Selection of the transformants 
Stably transfected cells were selected using the antibiotic blasticidin, based on the selective 
marker present in the vector backbone. The lethal dose, depending on the cell line, was determined 
by an individual experiment using a dilution row. The lowest concentration found to kill all non-
transfected cells within 10 days, 0.8 µl of 10 mg/ml Blasticidin per 1 ml medium, was then used 
to select for stable transformants. 
2.2.4.3 Validation of signal pathways stimulation of specific reporter cell lines  
The reporter cell lines were detached, counted and seeded in triplicate per treatment group into 
12-well format, 60 000 cells per well, in 1 ml DMEM medium/well without additives. As a con-
trol, cells without reporter construct were seeded. After 24 hours of incubation, stimulation was 
performed. 24, 48, and 72 hours after stimulation, reporter activity was assessed by sampling 
2 Material and methods 29 
 
supernatants for luciferase activation. Then, the cells were lysed, and RNA isolation, reverse tran-
scription and RT-PCR were performed as described in 2.2.5. 
2.2.4.4 Gaussia Luciferase Assays 
The reporter constructs use Gaussia Luciferase as a reporter protein (see 2.2.3.2.2). After addition 
of its substrate Coelenterazine to the cell culture supernatant, the measurement of the amount of 
light in relative light units (RLU) produced in this reaction was carried out using a luminometer. 
The commercially available BioLux Gaussia Luciferase Flex Assay Kit was used according to 
the manufacturer’s instructions. To prepare the Gluc assay solution, 50 µl assay puffer, 0.5 µl 
substrate and 8 µl stabilizer per sample were mixed. After incubating at room temperature for 25 
minutes protected from light, 50µl of the prepared solution was added to 20 µl of cell culture 
supernatant in 5 ml tubes. After incubation of minimum 45 seconds, the luminescence was meas-
ured using a Berthold Lumat LB 9507 Luminometer with 10 seconds measurement. As a control, 
50 µl of pure Gluc assay solution without supernatant was measured and subtracted from the 
result of the samples. 
 Quantitative real-time PCR 
Total RNA was isolated from the cells and reverse-transcribed to complementary DNA (cDNA). 
Then, qPCR was performed to quantify the resulting cDNA in real time and so determine the 
relative amount of mRNA for a specific gene.  
2.2.5.1 Total RNA purification 
To isolate RNA from the cells used in the cell-culture experiments, PureLink RNA Mini Kit 
(Thermo Fisher, Waltham, USA) was used according to the manufacturer’s instructions. To re-
move residual DNA from the sample, the optional digestion step with DNase I (Qiagen, Hilden, 
Germany) was included. In brief, the adherent cells were disassociated from the vessel using 
Trypsin and pelleted by centrifugation. Then, the cells were lysed with 600 µl lysis buffer con-
taining 1% 2-mercaptoethanol, the solution was homogenized by vortexing. Subsequently, the 
same volume of 96-100% ethanol was added to the sample and mixed thoroughly by vortexing. 
The sample was then processed through a spin cartridge with a collection tube to bind RNA to a 
membrane. After Centrifugation (12.000 xg for 15 seconds), the flow-through was discarded. 350 
µl wash buffer I was added to the spin cartridge. After centrifugation (12.000 xg for 30 seconds), 
the flow through was discarded. Then, 80 µl purelink DNase mixture (In RNAse free water re-
suspended DNase mixed with RDD buffer 1:8) was added directly to the surface of the spin car-
tridge membrane. After 15 minutes incubation at room temperature, another 350 µl of wash buffer 
I was added to the spin cartridge and the flow-through was discarded once again after centrifuga-
tion (12.000 xg for 30 seconds) Subsequently, the spin cartridge was inserted into a new collection 
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tube followed by two rounds of washing with wash buffer II with ethanol, centrifugation and 
discard of the flow-through. Then, to dry the membrane with attached RNA, the spin cartridge 
was centrifuged at 12.000 xg for 1 minute and inserted into a recovery tube. 35 µl RNase-free 
water was added to the center of the spin cartridge. After incubation for 1 minute at room tem-
perature, the spin cartridge and recovery tube were centrifuged at 12.000 xg for 2 minutes. There-
after, the purified RNA of each sample was so eluted in 35 µl RNase-free water. 
2.2.5.2 Reverse transcription  
The RNA samples were then processed to cDNA through reverse transcription. For the reverse 
transcription, the total amount of purified RNA in a volume of 30 µl RNase free water was added 
to 15 µl of the RT+ reaction mix (RT+ sample). 
A so called RT- control was added this reaction step to exclude PCR signal caused by contami-
nation with genomic DNA. For the RT- sample, RNA in a volume of 3 µl RNase free water was 
diluted with 27 µl RNase free water (dilution factor 1:10) and then added to a reaction mix equal 
to the RT+ reaction mix with the exception of the reverse transcriptase enzyme.  
 
Table  17: Reverse transcription, reaction mix 
Reagent RT+ RT- (1:10) 
First-strand buffer (5x) 9.0 µl 9.0 µl 
dNTP 25 mM 1.0 µl  1.0 µl 
DTT 0,1 M  2.0 µl 2.0 µl 
Rnasin 40 U/µl 1.0 µl 1.0µl 
Acrylamid (linear) 15 µg/ml 0.5 µl 0.5 µl 
Hexanucleotide 2µg/µl 0.5 µl 0.5µl 
Superscript 200 U/µl 1.0 µl - 
H2O RNasefree - 1.0 µl 
TOTAL 15µl mix/sample 15 µl mix/sample 
 
 
After adding the reaction mixes to the RT+ and RT- samples, both were incubated at 42 °C in a 
thermoblock and shaken for 90 minutes (350rpm). Then, the samples were stored at -20 °C until 
needed for further use. Since no reverse transcription could take place in the RT- sample and RNA 
is not measurable in qPCR, any signal produced by RT- had to come from DNA contamination 
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or cDNA unspecific primer. For subsequent qPCR reaction, a 1:10 dilution of the RT+ samples 
was needed (5 µl of the RT+ samples was diluted with 45 µl RNase free water), while the RT- 
samples were already diluted before reverse transcription and did not need further dilution to 
reach equal amount of RNA in the RT+ and RT- reactions.   
2.2.5.3 Quantitative PCR (qPCR) 
Quantitative PCR monitors the amplification of a targeted DNA molecule during the PCR by 
detecting fluorescent signals. There exist multiple variants of qPCR. Here, the LightCyclerÒ 480 
instrument with the SYBR Green method was used. SYBR Green is an intercalating dye, which 
specifically binds all double-stranded DNA. It exhibits very little fluorescence in its unbound state 
in solution and fluoresces only in its DNA bound state (measured at 530 nm at the end of each 
elongation phase). The fluorescent signal measured by the qPCR cycler device increases during 
the PCR cycles, correlating with the amount of dsDNA generated. This allows for calculation of 
the number of input copies of the target nucleic acid. Relative abundance of the original mRNA 
in a sample will result in an earlier detection of fluorescent signal than for samples with lower 
amounts. However, SYBR green detects all double-stranded DNA unspecifically, including non-
specific PCR products. To determine whether only the desired PCR product has been amplified, 
an additional step follows after the amplification cycles: A melting curve analysis is performed, 
based on the fact that each double-stranded DNA molecule has its characteristic melting temper-
ature (Tm), depending on length and GC content. The melting of dsDNA leads to sharp decrease 
of SYBR Green I fluorescence (=loss of signal) when the temperature reaches the melting tem-
perature of the PCR product. This is used as a control: If there was generated only one amplicon, 
a single peak appears in the melting curve analysis. The appearance of additional melting peaks 
indicates the presence of unspecific products or DNA contamination.  
To analyze the data from qPCR, relative quantification was used. In this method, the expression 
of candidate genes is normalized to a reference gene, a so called housekeeping gene, which is a 
constitutively expressed gene in all cells. The expression should be as similar as possible under 
all experimental conditions. Here, the housekeeping gen S18 was used. The master mix for the 
qPCR reaction was prepared as follows, using SYBR Green master mix (including the fluorescent 
dye), qPCR primers and thermostable DNA polymerase. H2O was added to reach a volume of 18 
µl. Then the master mix was mixed by vortexing for 1-2 seconds and subsequent brief centrifu-
gation.   
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Table  18: qPCR, reaction mix 
Reagent Amount per reaction per well  
SYBRGreen mastermix 10 µl 
SYBRGreen primer FW  0.6 µl (10 pM) 
SYBRGreen primer RV 10 pM 0.6 µl (10 pM) 
Taq Polymerase  0.12 µl (0.03 U/µl) 
H2O 6.68 µl  
TOTAL 18 µl 
 
 
 
96-Well PCR Plates were used as reaction plates; Experiments were set up in duplicates. All 
primers that were utilized are summarized in the table 9. First, 18 µl of the master mix was dis-
pensed into each well of the reaction plate. Then, 2 µl of the RT+ (1:10) dilution or 2 µl of the 
RT- samples was added to the master mix to reach a final volume of 20 µl per well. As a negative 
control, 2µl water was added to the master mix instead of 2 µl from the samples. The multiwell 
plate was sealed with a thin sheet of plastic and was then briefly centrifuged. Subsequently, the 
plate was loaded into the LightCyclerÒ 480 instrument; qPCR was performed, using the SYBR 
Green/HRM Dye protocol (excitation filter 465, emission filter 510), that exists of four steps: 1) 
Pre-Incubation for 5 minutes at 95 °C, which allows the activation of the Taq polymerase and the 
denaturation of the cDNA. 2) Amplification of the target DNA by cycling the samples 45 times at 
95°C for 15-30 seconds and at 72°C for 5-30 seconds, causing denaturation and annealing/exten-
sion and measuring fluorescence. 3) Melting curve analysis to identify the PCR product. 4) Cool-
ing of the plate with one cycle at 40°C.  
2.2.5.4 Quantification analysis  
During a PCR reaction, a certain amount of background fluorescence is seen. Therefore, an arbi-
trary threshold must be defined, representing a level above background fluorescence. During the 
amplification step in qPCR, this vertical threshold line is crossed by fluorescence in a certain 
cycle, so called crossing point-qPCR-cycle (Cp). The cycle where each reaction reaches the 
threshold depends on the amount of target DNA. Low Cp values indicate high amounts of target 
DNA, that rise above background in an early PCR cycle, whereas high Cp values indicate low 
amounts of target DNA, that rise above background in a late PCR cycle.  
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Figure 10: Amplification curves after performance of qPCR 
The fluorescence emission proportional to the PCR product was visualized in amplification curves. Am-
plification curves are obtained using a dilution series of each sample. They consist typically of 3 phases, 
initiation phase, exponential phase and plateau.  
 
 
Figure 11: Melting curve analysis of the amplicons  
Single peak. Unspecific products would be shown as additional peaks. 
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In relative quantification, a so called normalization to reference genes (housekeeper genes) was 
used. The target DNA template was compared with the reference gene in the same sample (Tar-
get/ref). That allowed comparisons across different samples. There exist different analysis modes 
for relative quantification. Here, advanced relative quantification analysis was performed using 
the LightCyclerÒ 480 software, following the manufacturer’s instructions. This analysis uses the 
so called efficiency method (E-method) that is based on standard curves, but takes into consider-
ation the differences in target and reference-gene amplification efficiency when calculating the 
final result.  
 Statistical analysis 
All stimulation experiments were conducted in triplicate to allow for assessment for significance. 
Data were analyzed by using GraphPad Prism software 5 (San Diego, CA, USA). Student’s un-
paired t-test was used for Gaussian distributed data. Statistical significance was identified in the 
graphs with p-values < 0.05 (*), < 0.01 (**) and < 0.001 (***) as determined by the software.  
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3 Results 
For the in vitro cell culture system, the human dermal fibroblast cell line K4IM was selected as 
dermal fibroblasts are found in the connective tissue of the skin, where they produce procollagen 
and GAGs. The Hek-293 cell line, originally isolated from human embryonal kidneys, was chosen 
as model for kidney parenchymal cells. To study inducibility by TGF-b and salt respectively, 
reporter plasmids were first stably integrated into both cell lines. The activity of the respective 
pathway was then used as a tool for internal control of successful stimulation of their respective 
intracellular pathways, independent of the resulting effect on XYLT1 expression.  
The Hek-293 cells carrying reporter plasmids did not display any XYLT1 inducibility (data not 
shown). Experiments performed under the same conditions, using reporter engineered K4IM 
cells, were more promising (see 3.2.). This led to the impression that the K4IM cell line was a 
better model system for studying XYLT1 induction rather than the Hek-293 cell line. As a result, 
only data from experiments carried out in transfected K4IM cells are included in the following 
sections.  
3.1 Validation of the reporter vectors 
After transfection of the individual reporter constructs into K4IM cells (see 2.2.4.1), the function-
ality of the reporter constructs was validated by stimulation of the individual pathway reporters. 
For each pathway, a stimulator for the pathway reporter was chosen: For the TGF-b/SMAD path-
way, recombinant human TGF-b1 was used to activate the reporter construct (figure 12). For 
activation of the NFAT5 reporter, a hyperosmolar environment was created by stimulation with 
sodium chloride (figure 13). In order to determine a functional range of TGF-b1 and sodium 
chloride, and to study the dose dependent nature of the response, the stimulation was performed 
in a titration experiment.  
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Figure 12: Validation of the TGF-b/SMAD reporter in TGF-b/SMAD reporter K4IM cells  
a) Significant activation of the reporter construct by TGF-b1 b) Stimulation reaches a plateau with 
doses > 2.5 ng/ml. To assess activity of the TGF-b/SMAD reporter, stably transfected K4IM cells were 
treated with, or without, TGF-b1 in increasing concentrations for 24h and 48h, after which reporter activity 
was assessed by measuring luciferase activity in the supernatant. A 96-well plate with 10 000 cells per well, 
with three wells per treatment group was used. Data are represented as relative light units (RLU). As a 
control, unstimulated not transfected K4IM cells were incubated under same conditions and subtracted from 
the data. P= 0.0023. Statistical analysis was performed using the unpaired t-test to compare the two groups. 
 
Figure 13: Validation of the NFAT5 reporter in NFAT5 reporter K4IM cells  
a) Significant activation of the reporter construct by hypertonic sodium b) Dose dependent enhance-
ment of reporter activity, with high NaCl doses (100 mM) found to be toxic to the cells. To assess 
activity of the NFAT5 reporter, stably transfected K4IM cells were treated with, or without, NaCl in var-
ying doses for 24h and 48h, after which reporter activity was assessed by measuring luciferase activity in 
the supernatant. A 96-well plate with 10 000 cells per well, with three wells per treatment group was used. 
Molar concentrations of NaCl described here were added to the standard NaCl concentration in the growth 
medium. Data are represented as relative light units (RLU). As a control, unstimulated not transfected 
K4IM cells were incubated under same conditions and subtracted from the data. P<0.001. Statistical anal-
ysis was performed using the unpaired t-test to compare the two groups. 
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Stimulation of both constructs led to significantly increased Gaussia luciferase signal, verifying 
their functionality.  
TGF-b1 concentrations above 2.5 ng/ml did not lead to a significant further increase of TGF-
b/SMAD reporter activation, suggesting saturation of the reporter construct.  
For the NFAT5 reporter, a dose-dependent enhancement of activation was shown, yielding the 
best stimulation results in sodium chloride concentrations between 50 mM and 100 mM. Toxic 
effects on the cells were observed at the highest concentration.  
These results provided suitable concentration ranges of TGF-b1 and sodium chloride, to be used 
for more accurate measurements of reporter construct activation in the following experiments.  
3.2 Stimulation experiments with TGF-b1  
As XYLT1 expression was shown to be modulated by the multifunctional cytokine TGF-b in the 
in vitro model of Fischereder et al. (2017), an important objective in this study was to assess 
reproducibility of these findings in our reporter engineered K4IM cells. This was accomplished 
through a series of stimulation experiments. TGF-b/SMAD reporter cells were treated with or 
without recombinant human TGF-b1 for 24, 48 and 72 hours. Resulting relative XYLT1 expres-
sion was quantified using qPCR. Simultaneously, the TGF-b/SMAD reporter construct was used 
as a tool for internal control of successful stimulation.  
A potent activation of the TGF-b/SMAD reporter was found, demonstrating successful stimula-
tion. There was also found significant induction of XYLT1 mRNA expression relative to 18S 
RNA after one-time treatment with TGF-b1, after 24, 48 and 72 hours with TGF-b1 present in 
the growth media (figure 14). 
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Further experiments were carried out in order to unfold the nature of XYLT1 induction by TGF-
b1 stimulation. In initial test stimulations, no difference could be detected between one-time stim-
ulation with 10 ng/ml TGF-b1 and two-time stimulation with 5 ng/ml TGF-b1 (data not shown).  
To evaluate how long XYLT1 expression remains increased after removal of TGF-b1 from the 
growth medium, TGF-b/SMAD reporter K4IM cells were treated with or without TGF-b1 for 48 
hours, before the supernatant was substituted by a TGF-b1 free medium. The XYLT1 expression 
relative to S18 was analyzed 24, 48 and 72 hours after medium exchange.  
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Figure 14: Treatment of TGF-b/SMAD reporter K4IM cells with recombinant TGF-b1 
 a): TGF-b1 stimulation led to a clear activation of the reporter construct. Accumulation of the pro-
tein produced by luciferase in the supernatant led to increase of RLU values after 48h and 72h. b): 
Relative induction of XYLT1 expression by TGF-b1, equally strong 24h, 48h and 72h after stimula-
tion. K4IM cells with integrated TGF-b/SMAD reporter were grown to confluence in DMEM, without 
addition of FCS and penicillin/streptomycin. Next, the cells were stimulated one time with, or without, 10 
ng/ml TGF-b1 and then incubated for 24h, 48h or 72h. Reporter activity was assessed by measuring lucif-
erase activity in the supernatant. The data are represented as relative light units (RLU). After lysis of the 
cells, RNA isolation, reverse transcription and relative quantification by qPCR was performed. Data rep-
resent steady state levels of hXYLT1-mRNA normalized to S18 RNA. 12-well plates with 60 000 cells 
per well, with three wells per treatment group were used. As a control, unstimulated K4IM cells without 
integrated reporter were incubated under same conditions and subtracted from the data. Statistical analysis 
was performed using the unpaired t-test between two groups. P <0.05 was considered significant. (a: 24h 
p= 0.005; 48 h p<0.001; 72h p <0.001; b: 24h p= 0.001; 48h p =0.0026; 72h p = 0.0014 compared to the 
neg. control). 
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XYLT1 expression was elevated as compared to the control values at 24 and 48 hours after re-
moval of TGF-b1, gradually decreasing with time and reaching normal expression levels similar 
to the unstimulated control 72 hours after removal of TGF-b1 (figure 15).  
These results support the general hypothesis that XYLT1 induction can be actively regulated by 
TGF-b1, which, considering the arguments outlined in 1., strengthens the theory that there may 
exist an active regulation of water-free sodium storage in connective tissues.  
3.3  Stimulation experiments with sodium chloride 
The overall objective for the following series of experiments was to determine whether a hyper-
osmolar environment could be a direct trigger for increased sodium storage via induction of 
XYLT1 expression in fibroblast cells. Such findings could suggest that non-osmotic sodium stor-
age could result as a direct buffer mechanism for regulating excessive extracellular sodium con-
centrations. To test this theory, K4IM cells with integrated NFAT5 reporter were used as detailed 
earlier, providing an internal control of successful NFAT5 pathway activation. The reporter cells 
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Figure 15: XYLT1 mRNA 24h, 48h and 72h after removal of TGF-b1  
XYLT1 expression is still considerably elevated, 24h after removal of TGF-b1 from the growth me-
dium. Gradual decline of XYLT1 expression after 24h: Expression is still significantly elevated com-
pared to the control 48 h after removal, and no longer elevated 72 h after removal. K4IM cells with 
integrated TGF-b/SMAD reporter were grown to confluence in DMEM, without addition of FCS and pen-
icillin/streptomycin. After one-time stimulation of the cells with, or without, 10 ng/ml TGF-b1 and incu-
bation for 48h, the growth medium was exchanged. The cells were lysed 24h, 48h or 72h after removal of 
TGF-b1. RNA isolation, reverse transcription and relative quantification by qPCR was performed. Data 
represent steady state levels of hXYLT1-mRNA normalized to S18 RNA. 12-well plates with 60 000 cells 
per well and three wells per treatment group were used. Statistical analysis was performed using the un-
paired t-test between two groups. P <0.05 was considered significant (24h p= 0.0052; 48h p =0.0373; 72h 
p=0.6811 compared to the neg. control). 
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were treated with or without sodium chloride for 48 hours, before levels of XYLT1 mRNA were 
analyzed by qPCR. Stimulation with TGF-b1 was used as a positive control for induction of 
XYLT1 expression. Stimulation with combined sodium chloride and TGF-b1 was also per-
formed, with the aim to uncover potential additive effects. Additionally, TGF-b3 was included in 
these experiments to asses if other TGF-b isoforms might have an effect on XYLT1 expression, 
similar to that seen with TGF-b1.  
 
 
 
 
a)                                                                                           b) 
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Figure 16: Treatment of NFAT5 reporter K4IM cells with sodium chloride, TGFb-1 and TGFb-3  
a) Treatment with hyperosmolar sodium chloride solutions alone, and in combination with TGFb-
1, and TGFb-3, activated the NFAT5 reporter construct. Treatment with TGFb-1 or TGFb-3 alone 
did not lead to reporter construct activation b) XYLT1 expression was induced both by TGFb-1 
and TGFb-3, whereas no induction by hyperosmotic stress was found. In fact, addition of sodium 
chloride to the treatment with TGFb-1 and TGFb-3 lowered their effect on XYLT1 expression. 
K4IM cells with integrated NFAT5 reporter were grown to confluence in DMEM, without addition of 
FCS and penicillin/streptomycin. Next, the cells were treated one time with 10 ng/ml TGF-b1, 10 ng/ml 
TGF-b3, 50 mM NaCl, 100 mM NaCl and then incubated for 24h, 48h or 72h. Reporter activity was 
assessed by measuring luciferase activity in the supernatant. Data are represented as relative light units 
(RLU). After lysis of the cells, RNA isolation, reverse transcription and relative quantification by qPCR 
was performed. Data represent steady state levels of hXYLT1-mRNA normalized to S18 RNA. 12-well 
plates with 60 000 cells per well, with three wells per treatment group were used. As a control, unstim-
ulated K4IM cells without integrated reporter were incubated under same conditions and subtracted from 
the data. Molar concentrations of NaCl described here were added to the standard NaCl concentration in 
the growth medium. Statistical analysis was performed using the unpaired t-test between two groups. P 
<0.05 was considered significant (a: p <0,0001 compared to the neg. control; b: TGF-b1 p=0.001; TGF-
b3 p= 0.0099 compared to the neg. control). 
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Successful NFAT5 pathway stimulation by sodium chloride treatment was demonstrated by the 
enhanced reporter activity (figure 16a). Nevertheless, hyperosmotic stress did not have a dis-
cernible effect on XYLT1 expression, contesting our hypothesis regarding this question. TGF-
b3 was further shown to have an equally strong induction of XYLT1 expression as was found 
with TGF-b1. Interestingly, the addition of sodium chloride to both TGF-b1 and TGF-b3 led to 
a decrease in steady state expression of XYLT1 mRNA (figure 16b). These findings contradict 
the theory that hyperosmolar environment functions as a direct trigger for increase of sodium 
storage, raising the question if there are more complex mechanisms regulating induction of 
XYLT1 expression, and sodium storage during hyperosmotic stress.  
With that background, the potential effects of sodium chloride treatment on TGF-b expression 
was then studied, under the hypothesis that TGF-b induction in response to osmotic stress may 
function as a link between a hyperosmolar environment and increased XYLT1 activity.  
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Figure 17: TGF-b mRNA after treatment with sodium chloride, TGFb-1 and TGFb-3  
TGF-b mRNA expression in NFAT5 reporter K4IM cells could not be induced by hyperosmotic 
stress. Data represent steady state levels of TGF-b-mRNA normalized to S18 RNA. qPCR was per-
formed on the samples generated in the stimulation experiment described in the figure 16, refer to 
there for detailed information. Statistical analysis was performed using the unpaired t-test between 
two groups. P <0.05 was considered significant (TGF-b1 p=0.0001; TGF-b3 p= 0.0082 compared to 
the neg. control). 
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The results showed no differences in TGF-b expression, with or without hyperosmotic stress, 
while, as expected, induction of TGF-b expression by TGFb-1 or TGFb-3 stimulation was found 
(figure 17). This data suggests, that TGF-b alone is not the link between hyperosmotic stress and 
regulation of sodium storage. We therefore concluded that more complex mechanisms than pre-
viously postulated such as the presence of endocrine regulators may be necessary for induction 
of XYLT1 expression by fibroblast cells.  
3.4 Stimulation experiments with endocrine regulators involved in sodium and 
phosphate homeostasis 
Since we were not able to induce XYLT1 expression by osmotic stress in the in vitro experiments 
described above, endocrine regulators involved in sodium and phosphate homeostasis were cho-
sen for a series of stimulation experiments, in the search for other stimuli than TGF-b, capable of 
inducing XYLT1 expression.  
 Treatment with AVP 
As a first candidate, arginine vasopressin (AVP) was tested. As it is known to be a key mediator 
in maintaining plasma osmolality, we hypothesized, that it may play a role in internal sodium 
balance, regulating the exchange between sodium linked to body water and sodium bound to pro-
teoglycans via XYLT1. Based on an earlier study, examining the treatment of isolated rat cardiac 
fibroblasts with AVP, (Yang, Zhao, Zheng, & Li, 2003), potential concentrations of AVP were 
established for our in vitro stimulation experiment. To test our theory, K4IM cells with integrated 
TGF-b/SMAD reporter were treated with AVP for 48 hours before levels of XYLT1 mRNA were 
analyzed by qPCR. Treatment with TGF-b1, with and without addition of AVP, was included in 
the experiment, allowing for discovery of potential additive effects.  
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a)                                                                                        b) 
 
 
 
Once again, TGF-b1 was shown to strongly induce XYLT1 expression. However, no effect of 
AVP treatment on the expression of XYLT1 could be identified in this model (figure 18b). One 
interpretation of these results is that AVP either has no role in regulation of XYLT1 expression, 
or that dermal fibroblasts are not the optimal choice of cell type for studying AVP stimulation, 
and that other cells known to be more responsive to AVP, e.g. vascular smooth muscle cells, 
would be a more suitable choice to investigate this matter.  
Although it is without relevance for the theory that AVP is actively regulating sodium storage via 
XYLT1, it is noteworthy that combined treatment with AVP and TGF-b1 led to significantly 
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Figure 18: Treatment of TGF-b/SMAD reporter K4IM cells with AVP and TGFb-1  
a) Sole treatment with arginine vasopressin (AVP) did not increase activation of the TGF-b/SMAD 
reporter construct, while synergistic effects of combined treatment with AVP and TGF-b1 were 
found. b) XYLT1 expression was neither induced by AVP in sole treatment, nor through synergistic 
effects with TGF-b1. TGF-b1 was used as positive control. Cells were stimulated with either 10 ng/ml 
TGF-b1, 10 nM AVP, 100 nM AVP or 10 ng/ml TGF-b1+10 nM AVP. After 48 h incubation, reporter 
activity was assessed by measuring luciferase activity in the supernatant. Data are represented as relative 
light units (RLU). After lysis of the cells, RNA isolation, reverse transcription and relative quantification 
by qPCR was performed. Data represent steady state levels of hXYLT1-mRNA normalized to S18 RNA. 
12-well plates with 60 000 cells per well, with three wells per treatment group were used. As a control, 
unstimulated not transfected K4IM cells were incubated under same conditions and subtracted from the 
data. Statistical analysis was performed using the unpaired t-test between two groups. P <0.05 was con-
sidered significant (a: TGF-b1+AVP p=0.0075; b: TGF-b1 p= 0.0014; TGF-b1+AVP p= 0.0082 compared 
to the neg. control). 
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stronger activation of the TGF-b/SMAD reporter construct than sole treatment with TGF-b1, sug-
gesting additive effects, while AVP alone could not increase activation of the TGF-b/SMAD re-
porter construct (figure 18a). 
 Treatment with ET-1 and FGF23 
As a further expansion of our search for potential regulators of XYLT1 expression, a second 
stimulation experiment was carried out, in which the effects of fibroblast growth factor 23 
(FGF23) and Endothelin 1 (ET-1) on XYLT1 expression were studied.  
FGF23 acts as an important mediator in phosphate homeostasis and is known to be dramatically 
elevated in chronic kidney disease (Olauson & Larsson, 2013). We hypothesized that it might 
work as a link between decreased renal function, altered renal phosphate handling and exchange 
of sodium storage.  
ET-1 on the other hand, is shown to be involved in the response to high salt intake, and to facilitate 
movement of Na+ through skin interstitium (Speed et al., 2015). Thus it is possible that ET-1 
could directly influence the regulation of sodium storage in arteries and skin. In earlier studies, 
ET-1 was shown to bind to dermal fibroblasts through specific high affinity surface receptors 
(Falanga, Katz, Kirsner, & Alvarez, 1992), and therefore seemed well suitable for our in vitro 
model.  
In the following experiment, K4IM reporter cells with integrated TGF-b/SMAD reporter were 
treated with FGF23 and ET-1, respectively, for 48 hours. Then, levels of XYLT1 mRNA were 
analyzed by qPCR. Sole treatment with TGF-b1 and TGF-b3, and treatment with TGF-b1 in 
combination with FGF23 and ET-1, respectively, was included in the experiment as a positive 
control for induction of XYLT1 expression and allowing for the study of potential synergistic 
effects. As in previous experiments, the TGF-b/SMAD pathway could be monitored by the re-
porter construct.  
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a)              b) 
 
 
No differences to the control in XYLT1 mRNA could be detected after ET-1 and FGF23 treat-
ment, respectively, while the positive control with TGF-b1 and TGF-b3 showed increased acti-
vation of the TGF-b/SMAD pathway and induction of XYLT1 expression. No additive effect of 
combined treatment nor significant activation of the TGF-b/SMAD pathway by ET-1 or FGF23 
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Figure 19: Treatment of TGF-b/SMAD reporter K4IM cells with ET-1, FGF23, TGFb-1 and TGFb-3  
a) Sole treatment with ET-1 and FGF23, respectively, did not increase activation of the TGF-
b/SMAD reporter construct, and no synergistic effects on the pathway were found by combined 
treatment with TGF-b1. b) XYLT1 expression could not be induced by sole treatment with ET-1 or 
FGF23, and no synergistic effects in combination with TGF-b1 on XYLT1 expression were found. 
TGF-b1 and TGF-b3 functioned as positive control. K4IM cells with integrated TGFb/SMAD reporter 
were grown to confluence in DMEM, without addition of FCS and penicillin/streptomycin. Next, the cells 
were stimulated one time with either 10 ng/ml TGF-b1, 10 ng/ml TGF-b3, 1 µg/ml FGF23 or 100 mM ET-
1 and incubated for 48h. Then, reporter activity was assessed by measuring luciferase activity in the su-
pernatant. Data are represented as relative light units (RLU). After lysis of the cells, RNA isolation, reverse 
transcription and relative quantification by qPCR was performed. Data represent steady state levels of 
hXYLT1-mRNA normalized to S18 RNA. 12-well plates with 60 000 cells per well, with three wells per 
treatment group were used. As a control, unstimulated not transfected K4IM cells were incubated under 
same conditions and subtracted from the data. Statistical analysis was performed using the unpaired t-test 
between two groups. P <0,05 was considered significant (a: p<0.0001 compared to the neg. control, b: 
TGF-b1 p< 0.0001; TGF-b3 p= 0.0136; TGF-b1+FGF23 p= 0.0002; TGF-b1+ET-1 p= 0.0010 compared 
to the neg. control). 
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was seen (figure 19b). Since the stimulation with ET-1 and FGF23 did not lead to increased 
XYLT1 activity, their role in regulation of sodium storage remains for the most part unknown.    
3.5 CHSY1 and CHPF2, enzymes involved in GAG biosynthesis 
While most of the external stimuli tested in our experiments were unable to induce XYLT1 ex-
pression, it was shown repetitively, that TGF-b1 strongly induces XYLT1 expression. In order to 
study if other genes involved in GAG synthesis could be induced by TGF-b1 stimulation, two 
genes engaged in chondroitin polymerization, CHSY1 and CHPF, were tested, as they play an 
important role in biosynthesis of chondroitin sulfate. CHSY1 is a gene encoding for chondroitin 
sulfate synthase 1, a member of the chondroitin N-acetylgalactosaminyltransferase family, and 
was in an earlier study shown to be induced by TGF-b1 in nucleus pulposus cells in rats (Hu et 
al., 2015).  Chondroitin polymerizing factor (CHPF), also known as CSS2 or CHSY2, encodes 
for chondroitin sulfate synthase 2 (Yada et al., 2003).  
CHSY1 and CHPF gene expression was analyzed by qPCR in the samples generated in the TGF-
b1 stimulation experiment (refer to 3.2.) . 
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Figure 20: CHSY1 and CHPF mRNA after treatment with TGF-b1  
Treatment with TGF-b1 did no show induction of CHSY1 (a) or CHPF (b) expression in K4IM TGF-
b/SMAD reporter cells after 24h, 48h and 72h incubation. Data represent steady state levels of 
hCHSY1-mRNA and hCHPF-mRNA normalized to S18 RNA. qPCR was performed on the samples gen-
erated in the stimulation experiment described in 3.2. Please refer to figure 14 for detailed information.  
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While mRNA levels were established for both enzymes, no differences in expression of CHSY1 
and CHPF could be detected by treatment with TGF-b1 (figure 20), suggesting that GAG expres-
sion induced by TGF-b1 is largely dependent on the activation of the key enzyme XYLT1 and 
that this first enzyme in the pathway of GAG biosynthesis represents a potential key regulator for 
sodium storage.  
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4 Discussion 
4.1 Overview of this work 
High correlation between tissue sodium concentrations, glycosaminoglycan content and the ex-
pression of XYLT1, the enzyme initiating glycosaminoglycan synthesis, was described in a recent 
study. The goal of the present study was to identify potential stimuli that modulate XYLT1 ex-
pression in fibroblast cells to better characterize XYLT1 biology in connective tissues- a putative 
source for sodium storage.  
As a first step, we established systems to monitor pathway activation status in human fibroblasts, 
functioning as internal controls of activation of the TGF-b and hyperosmotic stress signaling 
pathways. These tools could also serve as internal controls for future stimulation experiments, 
and could be helpful for studying alterations in homeostatic pathways.  
In the next step, the reporter-engineered cells were used in a series of stimulation experiments, 
where the reporter construct served as an internal control for successful pathway stimulation. 
XYLT1 mRNA expression was quantified by real-time PCR. 
 
 
 
 
Pre-existing data, in vivo study:
Tissue sodium concentrations correlated with GAG 
content and the expression of XYLT1
Development of an in vitro cell culture model
with tools to monitor pathway activity
(present in our laboratory)
Stimulation experiments with a series of external stimuli
-Internal control of sucessful stimulation
-Quantification of XYLT1 expression
Is XYLT1 actively regulated?
Figure 21: Experimental outline 
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We observed induction of XYLT1 mRNA expression in fibroblast cells by treatment with TGF-
b1 and TGF-b3. Media with hypertonic sodium, elevated Vasopressin, Endothelin-1 and FGF23 
concentrations, respectively, did not have significant effect on XYLT1 expression. Our data sup-
port the hypothesis that XYLT1 is actively regulated by TGF-b in fibroblasts, which strengthens 
the theory that there is active regulation of water-free sodium storage. Because upregulated TGF-
b1 in kidney disease is shown to contribute to progression of renal fibrosis, it may represent the 
link between renal disease, elevated GAG synthesis and Na+ excess in tissue as a consequence 
thereof. 
4.2 Relevance of water-free sodium storage 
Osmotically inactive sodium storage pools exist without doubt (Titze, 2014), and incorporation 
of sodium into glycosaminoglycans has been proposed (Mobasheri, 1998). However, the biolog-
ical processes of these pools and their relevance for disease remain unclear.  
 Exchangeability of sodium pools 
Regarding the potential biology underlying these processes, it is of central importance to deter-
mine whether the size of the sodium storage pools is constant, or can change under varying con-
ditions. There is evidence that the sodium pools are exchangeable, as changes in tissue Na+ content 
could be demonstrated under varying study conditions. For example, a mobilization of sodium 
storage is seen during starvation (Garnett, Ford, Golding, Mardell, & Whyman, 1968), and tissue 
Na+ content has been shown to decrease in hypertensive patients with primary hyperaldosteronism 
after operative or spironolactone treatment (C. Kopp et al., 2012).  
 The potential biology behind this process 
Assuming an exchangeability of sodium storage, a natural question to ask, is what conditions lead 
to shifts in the amount of non-osmotically bound sodium. Schafflhuber et al. (2007) proposed that 
Na+ tissue content varies as a response to states of sodium retention or loss and suggested that 
sodium storage pools play a role in the regulation of plasma volume and blood pressure. With this 
in mind, it is possible that sodium storage may function as a buffer to help compensate for an 
imbalance between sodium in- and output. A different perspective on the potential mechanisms 
driving sodium storage was postulated by Wiig et al. (2013), suggesting that an increase in Na+ 
tissue content is linked to the activation of the immune system, and ultimately leads to increased 
sodium clearance through the skin.  
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 Physiological phenomenon or related to disease? 
Whether sodium storage is a physiological response or related to disease is a controversial topic. 
On the one hand, Fischereder et al. (2017) and Dahlmann et al. (2015) have suggested that it may 
respresent an individual physiological response, rather then a component or process associated 
with progressive kidney disease. In their studies, no difference in tissue sodium content was found 
between dialysis patients and healthy controls. Instead, a high interindividual variation and age 
dependency of tissue Na+ content that correlated with increasing age was observed. 
By contrast, Schneider et al. (2017) have suggested that Na+ excess may contribute to cardiovas-
cular morbidity in CKD, as a correlation of skin sodium concentrations with left ventricular mass 
in patients with chronic kidney disease was found. Supporting this, osmotically inactive Na+ stor-
age was suggested to contribute to the development of salt sensitive hypertension (Titze, Krause, 
et al., 2002).  
We speculate that the pathophysiology behind these observations, could in part be explained by 
the following: the GAG content in arteries was shown to correlate with tissue Na+ content in 
arteries (Fischereder et al., 2017). The accumulation of proteoglycans in the vascular wall corre-
lates with hypertension, and glycosaminoglycan overproduction has been shown to be associated 
with increased aortic calcification (Purnomo et al., 2013). It could then be suggested that Na+ 
excess may represent a trigger for vascular stiffening and hypertension, and microvascular disease 
as a consequence. An additional question in this regard is whether sodium incorporation into 
GAGs could change the mechanical properties of GAGs, reinforcing the stiffening of arterial 
walls.  
To gain insight into this topic, it would be of interest to extend the study of Schneider et al. (2017) 
by investigating correlation of left ventricular mass not only with Na+ content in the skin, but also 
with tissue Na+ content in arteries.  
An alternate interpretation of the observations described by Schneider et al. (2017) and Titze, 
Krause, et al. (2002) is that they may be describing essentially a saturated physiological Na+ buffer 
linked to an active regulation of sodium storage a process seen after compensating for high serum 
sodium concentrations through storing sodium over time, as a means of preventing hypertension. 
 Intervening sodium storage - a way to prevent disease in the future? 
Whether sodium storage is a physiological phenomenon or a part of disease, it may represent a 
way of preventing disease; Either through supporting a normal physiological process, or through 
inhibiting a pathophysiological process. Therefore, the study of the regulatory mechanisms of 
sodium storage via the regulation of a gene like XYLT1, which encodes for the first enzyme in 
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the committed biosynthesis of GAGs, could provide information and potentially targets for clini-
cal intervention, e.g. to reduce Na+ tissue content in patients with cardiovascular disease or renal 
disease, if Na+ excess is a factor for progression of the disease.   
4.3 TGF-b - possible link between renal disease and increased sodium storage? 
The role of canonical TGF-β signaling pathways in the regulation of non-osmotic sodium storage 
is not well understood. In our in vitro study detailed here, XYLT1 mRNA expression was  shown 
to be strongly inducible by TGF-b1 and TGF-b3. This observation supports previous studies, 
where TGF-b was shown to modulate XYLT1 expression in vitro (Fischereder et al., 2017), (Faust 
et al., 2013). While Faust et al. (2013) interpreted this observation in context of the pathology of 
skin fibrosis and fibrotic remodeling, we propose that regulation of sodium storage by TGF-b1 
via XYLT1 may also be directly linked to increased tissue Na+ content (Fischereder et al., 2017).  
TGF-b1 is associated with kidney disease  and shown to contribute to the progression of renal 
fibrosis (Meng, Nikolic-Paterson, & Lan, 2016). It may also provide a link between renal disease, 
elevated GAG synthesis and Na+ storage in tissues.  We propose that TGF-b signaling may be 
working in a paracrine manner in this context, e.g. through release from endothelial cells, rather 
than through a systemic elevation of TGF-b levels.  
4.4 Another look at XYLT1  
 XYLT1 – a key enzyme regulating sodium storage 
Study of the regulation of XYLT1 regulation was the main subject of this thesis. This enzyme 
encodes for a protein that appears to represent the rate-limiting step in the biosynthesis of GAGs. 
These structures have been suggested to provide a structure for non-osmotic sodium storage in 
tissues. Elevated GAG synthesis increases a negative charge density in tissues, which could lead 
to increased Na+ incorporation (Titze et al., 2004).  
In addition to XYLT1, we also studied the expression of other enzymes involved in GAG synthe-
sis. Unlike a previous study, where a positive correlation between skin Na+ content, CHSY1 ex-
pression and proteoglycan content was observed (Titze et al., 2004), we were not able to show 
modulation of CHSY1 or CHPF expression in vivo or in vitro. XYLT1 expression, however, was 
shown to be strongly inducible. Our findings support the results described by Fischereder et al. 
(2017) which showed altered expression of XYLT1 which positively correlated with tissue Na+ 
content in vivo, that included the parallel evaluation of a series of genes involved in GAG synthe-
sis, including CHSY1 and CHPF. 
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We therefore assume that XYLT1, known to be the rate-limiting enzyme in GAG synthesis, rep-
resents the key enzyme regulating potential sodium storage in tissues. We were able to induce 
XYLT1 expression in fibroblast cells by stimulation with TGF-b, suggesting that there is an active 
biological regulation of XYLT1 expression.  
 Consequences of XYLT1 expression  
If we now assume the general importance of of XYLT1 expression in the regulation of sodium 
storage, one could question whether tissue sodium storage pools may change directly in response 
to XYLT1 expression, e.g. as seen in hereditary diseases with mutations of XYLT1, causing loss 
of function, or polymorphisms causing increased XYLT1 expression. 
A hereditary disease, known to be caused by complete loss of function of XYLT1, is called des-
buquois dysplasia type 2. It is a rare type of osteochondrodysplasia, which causes significant 
reduction of cellular proteoglycan content in skin fibroblasts (Bui et al., 2014). One might assume 
then that patients with this disease may also show a decreased tissue Na+ content. However, no 
such study has been conducted to date. In order to further investigate consequences of hypoex-
pression of XYLT1, a XYLT1 knock-down construct was designed in our laboratory and trans-
fected into the K4IM cells. Due to technical problems, we were not able to demonstrate function-
ality of the knock-down system, but with an improved construct, it could be an interesting ap-
proach in the future. 
Increased XYLT expression due to polymorphisms, was identified in the heritable connective 
tissue disorder called pseudoxanthoma elasticum (Schon et al., 2006). The consequences of this 
condition in terms of sodium storage is also not reported, but in one study, no association with 
essential hypertension was found (Ponighaus et al., 2009).  
4.5 Reporter plasmids as internal control of successful stimulation 
Unfortunately, in many studies, negative results which are centrally important are also difficult 
to report, as it is hard to define whether it is a true negative result or a consequence of dysfunc-
tional methods. Therefore, to avoid this problem, one of our goals was to establish a system of 
internal control for the treatment in dermal fibroblasts. Using reporter plasmids, we not only de-
veloped safe and well-functioning constructs to control successful stimulation, but we were also 
able to study possible increased activation of relevant regulatory pathways. Additional to the 
study of XYLT1 mRNA expression, our constructs allowed us to monitor signaling pathways, 
potentially relevant in the regulation of sodium storage, namely the TGF-b/SMAD pathway and 
the pathway for osmotic-stress response (NFAT5). The following techniques contribute to the 
generation of the constructs (Jackel et al., 2016): 
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1) The AMAXA Nucleofection was used to transfect our experimental dermal fibroblasts 
with the various plasmids. The system was optimized for small volumes and the specific 
protocol applied for the desired cell line allowed for high efficiency and good cell viabil-
ity. This was very important when using the K4IM cells, as they are difficult to transfect 
and proliferate slowly.  
2) The Sleeping Beauty transposon technology (Mates et al., 2009) allowed for stable and 
efficient transfections by near-random integration in the host DNA.  
3) With the use of a secreted reporter protein (Gaussia luciferase), as the read-out (Tannous, 
Kim, Fernandez, Weissleder, & Breakefield, 2005) we were able to measure pathway 
activity without cell lysis before proceeding to RT-PCR. Before measurement, cell den-
sity was controlled by microscopy, as the results are not standardized to cell number.  
As expected, control activation of the TGF-b/SMAD reporter by TGF-b, and of the NFAT5 re-
porter by hypertonic sodium during XYLT1 induction was demonstrated (see 3.2. and 3.3.), 
whereas no effects of most of the other stimuli were found. Interestingly, addition of AVP with 
TGF-b1 led to stronger activation of the pathway than did sole treatment with TGF-b1 (see 3.4.1). 
A link between AVP and TGF-b has been previously described in the literature: AVP was shown 
to induce TGF-b secretion by proliferating mesangial cells, possibly contributing to glomerulo-
sclerosis in renal disease  (Tahara, Tsukada, Tomura, Yatsu, & Shibasaki, 2008). However, the 
additive effects of AVP and TGF-b1 on the TGF-b/SMAD signaling pathway are not yet under-
stood and a subject of further investigations.  
Another finding that cannot be explained by our current knowledge on the topic, is that, addition 
of sodium chloride with TGF-b treatment lowered the effect on XYLT1 expression. Although 
XYLT1 expression was not inducible by treatment with hypertonic sodium, the NFAT5 reporter 
showed activation of the pathway, indicating successful stimulation.  
The excellent functionality of our reporter engineered K4IM cells allowed them to be useful tools 
for future stimulation experiments and pathway studies.  
4.6 Limitations of our in vitro model 
The in vitro cell culture study applied here allowed for detailed and controlled analysis of the 
fibroblast response to various stimuli. Importantly, the results from in vitro experiments are not 
always transferable to complex organisms. 
Using this system we sought to identify stimuli that modulate steady state XYLT1 mRNA ex-
pression. No effect of treatment with hypertonic sodium, AVP, FGF23 and ET-1 on XYLT1 ex-
pression was found, suggesting that they do not actively regulate GAG expression in fibroblasts.  
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It is possible, that effects are difficult to see in a direct in vitro setting, as these processes could 
work in other cell settings or through complex interactions between several cell types and local 
mediators in vivo. In this regard, it is interesting that XYLT1 expression correlated with calculated 
osmolality in vivo in skin, muscle and arteries (Fischereder et al., 2017). The regulators tested in 
our study were not directly measured in the previous in vivo study. 
Sodium storage is suggested to take place in different tissues such as skin, muscle and arteries, 
and models with other cell types present in these tissues would be useful to study the regulation 
of sodium storage. For example, co-culture experiments with our reporter engineered fibroblasts 
and endothelial cells could be an interesting system to re-evaluate the potential effects of these 
agents. 
4.7 Outlook: Quantification of sodium concentrations and GAG content in vitro 
To further strengthen our theory, the next intuitive step is to investigate the potential correlation 
between XYLT1 expression, sodium concentration and GAG content in vitro.  
Relevant question in this topic include:  
1) Quantification of sodium concentrations in vitro: For example experiments using radio-
active sodium to measure changes in sodium content in vitro (in cooperation with the 
institute of Pharmaceutical Radiochemistry, Technische Universität München).  
2) Quantification of GAG content in vitro: Either by using a suitable glycosaminoglycan 
antibody (FACS) or by developing an appropriate staining method. 
3) Establishment of a functioning XYLT1 knock-down construct to investigate conse-
quences of reduced XYLT1 expression on sodium concentrations.  
4) Expansion of the in vitro experiments with a broader range of cell types, by using e.g. 
endothelial cells.  
5) Study of the effect of the endocrine regulators AVP, FGF23 and ET-1 on XYLT1 ex-
pression in vivo e.g. in human studies or animal studies. 
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